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TARGETING TELOMERASE IN HER2 POSITIVE BREAST CANCER:  
ROLE OF CANCER STEM CELLS 
 
 
Cancer stem cells (CSCs) are proposed to play a major role in tumor 
progression, metastasis, and recurrence.  The Human Epidermal growth factor Receptor 
2 (HER2) gene is amplified and/or its protein product overexpressed in approximately 
20% of breast cancers.  HER2 overexpression is associated with increased CSCs, which 
may explain the aggressive phenotype and increased likelihood of recurrence for HER2+ 
breast cancers.  Telomerase is reactivated in tumor cells, including CSCs, but has 
limited activity in normal tissues, providing support for the use of telomerase inhibition in 
anti-cancer therapy.  Telomerase inhibition via an antagonistic oligonucleotide, imetelstat 
(GRN163L), has been shown to be effective in limiting cell growth in vitro and limiting 
tumor growth.  Moreover, we have previously shown imetelstat can decrease 
metastases to the lungs, leading us to question if this is due to imetelstat targeting the 
CSC population.  In this thesis, we investigated the effects of imetelstat on CSC and 
non-CSC populations of HER2+ breast cancer cell lines, as well as a triple negative 
breast cancer cell line, which lacks HER2 overexpression.  Imetelstat inhibited 
telomerase activity in both CSC and non-CSC subpopulations.  Moreover, imetelstat 
treatment alone and in combination with trastuzumab significantly reduced the CSC 
fraction and inhibited CSC functional ability, as shown by a significant decrease in 
mammosphere counts and invasive potential.  Tumor growth rate was slower in 
combination treated mice compared to either drug alone.  Additionally, there was a trend 
toward decreased CSC marker expression in imetelstat treated xenograft cells 
vi 
 
compared to vehicle control.  The decrease in CSC marker expression we observed 
occurred prior to and after telomere shortening, suggesting imetelstat acts on the CSC 
subpopulation in telomere length dependent and independent mechanisms.  Our study 
suggests addition of imetelstat to trastuzumab may enhance the effects of HER2 
inhibition therapy.  
 
 
Brittney-Shea Herbert, Ph.D., Chair 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
Breast Cancer Statistics and Subtypes 
 Accounting for nearly 1 in every 4 deaths, cancer remains the second leading 
cause of death in the United States.  An estimated 1.65 million new cancer cases will be 
diagnosed and 585,000 people will die of cancer in 2014 in the United States alone.  The 
lifetime probability of developing cancer is 1 in 2 for men and 1 in 3 for women.  
Although 5-year survival rates have drastically improved since the 1970s due to 
advances in early detection and treatment, metastatic and recurrent disease remain 
difficult to treat (American Cancer Society, www.cancer.org). 
 Breast cancer is one of the most commonly diagnosed cancers in women, 
second to skin cancers.  During their lifetime, about 1 in 8 (12%) of women will develop 
invasive breast cancer.  An estimated 232,000 new cases of invasive breast cancer and 
62,000 new cases of non-invasive carcinoma in situ will be diagnosed this year.  Breast 
cancer is the second leading cause of cancer deaths in women, accounting for 15% of 
cancer fatalities and claiming an estimated 40,000 lives this year.  Survival rates 
correlate with disease stage at diagnosis.  Localized disease (Stage 0 or I) has a 5-year 
relative survival rate of nearly 100%.  Relative 5-year survival rates for regional disease 
(Stage II and III) are 93% and 72%, respectively.  The 5-year relative survival rate 
dramatically decreases when cancer is detected in distant organs or lymph nodes (Stage 
IV) to 22% (American Cancer Society, www.cancer.org). 
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 Many factors have been linked to an increased risk of breast cancer.  These 
factors include lifestyle factors such as weight, exercise level, smoking, alcohol use, 
contraceptive use, pregnancy history, and hormone replacement therapy.  Other 
personal risk modifiers include race, age, high breast tissue density, and family history of 
breast cancer.  An estimated 5-10% of breast cancers are due to inherited mutations, 
such as BRCA1 and BRCA2 mutations in familial breast and ovarian cancer and p53 
mutations in Li-Fraumeni syndrome (American Cancer Society, www.cancer.org).   
Breast cancer is traditionally classified based on receptor expression status of 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2).  While receptor status remains fundamental to classification and 
treatment determination in breast cancer, seminal work by Perou and colleagues 
expanded our understanding of the heterogeneity and complexity of this disease.  Based 
on hierarchical clustering analysis of cDNA microarray data, Perou and collaborators 
discovered five distinct molecular subtypes of breast cancer: basal-like, HER2, normal-
like, Luminal A, and Luminal B (Perou et al., 2000).  Further work showed the intrinsic 
subtypes highly correlated with clinical outcomes, including poor prognosis in the basal-
like and HER2+ cancer subtypes, as well as significant differences in survival between 
the luminal subtypes (Sorlie et al., 2001).   
 
HER2 Positive Breast Cancer 
 The HER2 (Human Epidermal Growth Factor Receptor 2) gene, also known as 
ERBB2 and neu, encodes a 185 kDa receptor tyrosine kinase (Akiyama et al., 1986).  
HER2 is a member of the human epidermal growth factor receptor family, including 
EGFR (also known as HER1), HER3, and HER4.  HER receptors exist as monomers at 
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the cell surface and dimerize upon ligand binding.  HER2 does not have a known ligand, 
but it is the preferential heterodimerization partner for all HER family receptors (Yarden, 
2001).  Upon dimerization, the receptors auto and cross-phosphorylate, which activates 
many downstream signaling molecules, including the ras-MAPK and PI3K-AKT 
pathways, leading to cell cycle progression, cell survival, and proliferation (Reese and 
Slamon, 1997).  Figure 1.1 shows the signaling pathways activated upon receptor 
dimerization.     
The HER2 gene is found amplified and/or its protein product the HER2 receptor 
overexpressed based upon IHC and FISH analyses in approximately 20% of all breast 
cancers, with the classification as the HER2 positive (HER2+) breast cancer subtype.  
HER2 amplification/overexpression is a predictor of decreased overall survival, 
decreased time to relapse, increased early metastases, and poor prognosis (Slamon et 
al., 1987; Slamon et al., 1989; Tiwari et al., 1992).  Additionally, HER2 expression level 
positively correlates with tumor grade, S-phase (dividing) cell fraction, and aneuploidy 
(Ross et al., 2009).  Tumors with HER2 overexpression are oncogene addicted due to 
their dependency on HER2 function, shown by knockdown of HER2 receptor by siRNA, 
kinase-dead HER2, and anti-HER2 antibodies in vitro and inducible tumor models in vivo 
leading to apoptosis and tumor regression in HER2 overexpressing cancer cells, but not 
tumor cells without HER2 overexpression (reviewed in (Moasser, 2007)).   
The oncogene addiction and poor clinical prognosis of HER2+ breast cancers 
necessitated therapeutic targeting of the HER2 receptor.  Trastuzumab (Herceptin™, 
Genentech) was the first available HER2-targeted therapy.  Trastuzumab is a 
humanized murine monoclonal antibody that binds to the extracellular domain of the 
HER2 receptor.  While its mechanism of action is not completely established, 
trastuzumab is thought to exert its antitumor activity through activation of antibody-  
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Figure 1.1.  HER2 Signaling Pathway.  Upon receptor dimerization and 
phosphorylation, ras-MAPK and PI3K-Akt pathways are activated, leading to 
proliferation, cell cycle progression, and survival. Adapted from (Lin and Winer, 2007).  
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dependent cell cytotoxicity, abrogation of intracellular signaling, inhibition of proteolytic 
cleavage of the extracellular domain, decreased DNA damage repair, and reduction of 
tumor angiogenesis (Bianchini and Gianni, 2014; Spector and Blackwell, 2009).  
Pertuzumab (Perjeta™, Genentech) is another monoclonal antibody targeting the 
extracellular domain of HER2, but at a different epitope than trastuzumab.  Pertuzumab 
blocks receptor dimerization and gained FDA approval in 2012 for first line HER2+ 
metastatic breast cancer treatment when used in combination with trastuzumab and 
docetaxel due to prolonged progression free survival (Baselga et al., 2012).  Ado-
trastuzumab emtansine (Kadcyla™, Genentech), abbreviated T-DM1, is a novel 
antibody-drug conjugate consisting of the monoclonal antibody trastuzumab stably linked 
to the cytotoxic microtubule inhibitor DM1 (derivative of maytansine).  T-DM1 improves 
the therapeutic index and minimizes exposure to normal tissue by specifically delivering 
the cytotoxic drug to HER2 overexpressing cells.  T-DM1 gained FDA approval as a 
second line HER2+ metastatic breast cancer therapy in 2013 based on prolonged 
progression free survival and overall survival (Verma et al., 2012).  Lapatinib (Tykerb™, 
GlaxoSmithKline) was the first available tyrosine kinase inhibitor for HER2+ breast 
cancer.  Lapatinib is a small molecule inhibitor of both HER2 and EGFR that reversibly 
binds to the receptor’s intracellular ATP-binding pocket and prevents downstream 
signaling by inhibiting receptor autophosphorylation (Li and Li, 2013).  The novel next-
generation tyrosine kinase inhibitors, neratinib (HKI-272, Puma Biotechnology) and 
afatinib (Gilotrif, Boehringer Ingelheim Pharmaceuticals), are irreversible pan-HER 
kinase inhibitors that covalently bind cysteine residues in the ATP-binding pockets of 
EGFR and HER2, as well as HER4 with neratinib, and inhibit receptor 
autophosphorylation.  While monotherapy clinical trials of these agents have been 
promising, combination therapies have not proven more efficacious thus far and both 
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agents lack FDA approval for treatment of HER2+ breast cancer (Zhang and Munster, 
2014).  Figure 1.2 summarizes the HER2 targeted therapy options. 
 While HER2 targeted therapy revolutionized outcomes in HER2+ breast cancer, 
many patients are either initially resistant or acquire resistance to trastuzumab leading to 
disease progression.  Many mechanisms of trastuzumab resistance have been proposed 
(See Figure 1.3).  One such mechanism involves a disrupted interaction between HER2 
and trastuzumab through either glycoprotein Mucin-4 (MUC4) overexpression which 
sterically hinders antibody binding to HER2 extracellular domain or overexpression of 
p95 HER2, a truncated HER2 receptor that lacks the extracellular domain and thus the 
trastuzumab binding site (Mukohara, 2011; Nahta et al., 2006).  Another mechanism of 
trastuzumab resistance is through compensatory signaling from other HER family 
members, such that inhibition of PI3K and MAPK by trastuzumab blocking HER2 may be 
bypassed by activating signals from HER1 and HER4 (Awada et al., 2012).  
Overexpression of insulin-like growth factor 1 receptor (IGF1R), which also activates the 
PI3K pathway, leads to trastuzumab resistance (Lu et al., 2001; Nahta et al., 2005).  
Additionally, loss of PTEN function, PIK3CA mutations, cyclin E 
amplification/overexpression, and p27 downregulation may also contribute to 
trastuzumab resistance (Mohd Sharial et al., 2012; Nahta and Esteva, 2006; Scaltriti et 
al., 2011).  ER signaling is thought to be involved in lapatinib resistance (Xia et al., 
2006).  Resistance remains a serious concern and many strategies for overcoming it are 
being investigated, including combining HER2 inhibitors, combination with endocrine 
therapy in ER+ patients, and inhibitors of the PI3K/AKT/mTOR pathway (Mohd Sharial et 
al., 2012).   
Additional challenges of HER2 targeted therapy relate to cardiotoxicity and the 
blood-brain barrier.  HER2 has been shown essential to normal heart ventricle 
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Figure 1.2. HER2 Targeted Therapies.  HER2 can be inhibited many ways, including 
use of monoclonal antibodies (trastuzumab, pertuzumab, and T-DM1) and tyrosine 
kinase inhibitors (lapatinib, neratinib, and afatinib).  Adapted from  (Zelnak and Wisinski, 
2014). 
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Figure 1.3.  Proposed Mechanisms of Trastuzumab Resistance.  Disrupted 
interaction of antibody and receptor, increased signaling though other growth factor 
receptors, and alterations in downstream signaling molecules are all possible 
mechanisms of resistance.  Adapted from (Mohd Sharial et al., 2012). 
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development and conditional mutant mice develop severe dilated cardiomyopathy, 
suggesting the importance of HER2 in normal cardiac function and potential cardiac 
toxicities with HER2 targeted therapy (Ozcelik et al., 2002).  Indeed, the pivotal phase III 
trial leading to trastuzumab FDA approval found asymptomatic or symptomatic cardiac 
dysfunction occurred in 27% of patients receiving trastuzumab plus anthracycline and 
cyclophosphamide versus 8% in anthracycline and cyclophosphamide alone and 13% of 
the group given trastuzumab plus paclitaxel versus 1% of patients given paclitaxel alone 
(Slamon et al., 2001).  A meta-analysis of five randomized clinical trials of trastuzumab 
therapy in HER2+ breast cancer revealed a significant increased risk of congestive heart 
failure and significant increased risk of grade significant left ventricular ejection fraction 
reduction in the trastuzumab arm (Bria et al., 2008).  Trastuzumab related cardiac 
toxicities appear to largely be reversible, with one study finding mean time to recovery of 
left ventricular ejection fraction was 1.5 months following cessation of trastuzumab and 
increases in left ventricular ejection fraction in 37 out of 38 patients (84% of which 
underwent medical treatment for left ventricular dysfunction) (Ewer et al., 2005).  The 
most important risk factors for developing trastuzumab-induced cardiomyopathy include 
age, previous exposure to anthracyclines, and borderline ejection fraction before 
treatment (Guglin et al., 2008).  Clinical trial data have demonstrated HER2 positive 
metastatic breast cancer patients are two to four times more likely than HER2 negative 
disease patients to develop brain metastases (Mehta et al., 2013).  Additionally, a large 
retrospective trial of early stage breast cancer patients found HER2 positive disease is a 
significant risk factor for central nervous system relapse.  Patients with HER2+ tumors 
had a 2.7% 10-year cumulative incidence of central nervous system disease as the site 
of first relapse compared to 1.0% in HER2 negative tumors and 6.8% cumulative 
incidence of central nervous system metastases compared to 3.5% in HER2 negative 
patients (Pestalozzi et al., 2006).   Studies indicate trastuzumab does not itself increase 
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the risk of brain metastasis, but is likely a consequence of prolonged survival, revealing 
the central nervous system as a sanctuary site due to the inability of trastuzumab to 
penetrate the blood-brain barrier (Lin and Winer, 2007; Mehta et al., 2013).  Indeed, one 
study found the median trastuzumab level ratio in serum to cerebrospinal fluid was 420:1 
and 76:1 after whole brain radiotherapy, which is thought to disrupt the blood-brain 
barrier (Stemmler et al., 2007).  With improvements in patient survival, resistance and 
central nervous system disease remain key challenges of HER2 targeted therapies.  
While HER2+ tumors have an oncogene dependence on HER2, these tumors, like all 
cancers, must also achieve limitless replicative potential to continue to grow and thrive.  
The potential for replicative immortality is mainly achieved by telomerase reactivation 
and maintenance of telomere length.  Inhibiting telomerase activity and thus decreasing 
telomere length could aid in anti-HER2 treatment by blocking another dependence of 
these tumor cells.   
 
Telomeres and Cancer 
 Telomeres are DNA-protein complexes that cap and protect the ends of linear 
chromosomes (Figure 1.4) (Blackburn, 1991).  A repetitive TTAGGG sequence, up to 20 
Kb in length, followed by a 3′ single-stranded G-rich overhang comprise the DNA 
component of human telomeres (Makarov et al., 1997; Moyzis et al., 1988).  A T-loop 
structure is formed by invasion of the single-stranded overhang into the double-stranded 
telomeric repeats, protecting the telomere from unregulated nuclease digestion of the 3′ 
overhang and end-to-end fusions (Griffith et al., 1999; Wei and Price, 2003).  The protein 
component of human telomeres is comprised of six proteins (TRF1, TRF2, POT1, TIN2,  
 
 
11 
 
 
 
 
 
 
 
 
Figure 1.4.  Telomeres Protect Chromosome Ends.  Telomeres are comprised of 
TTAGGG telomeric repeats ending with a 3′ G-rich overhang that invades into the 
double stranded repeats to form a T-loop structure.  Telomeric DNA, along with the 
shelterin proteins (TRF1, TRF2, TIN2, TPP1, POT1, and RAP1), cap the ends of linear 
chromosomes and prevent them from being recognized as double-strand breaks.  
Adapted from (Denchi, 2009).   
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TPP1, and RAP1) that form the shelterin complex, which is responsible for t-loop 
formation and telomere protection against DNA repair machinery recognizing telomeres 
as double-strand breaks (de Lange, 2005).  TRF1 and TRF2 show specificity for binding 
double-stranded TTAGGG replicative DNA, while POT1 shows specificity for single-
stranded TTAGGG repeats (Palm and de Lange, 2008).  TIN2, TPP1, and RAP1 are 
recruited to the telomere by TRF1 and TRF2 and act as tethering proteins to keep the 
shelterin complex stable (de Lange, 2005).  TIN2 joins TRF1 and TRF2; TPP1 links TIN2 
to POT1; and Rap1 interacts with TRF2 and represses homology-directed repair at 
chromosome ends (Denchi, 2009; Kabir et al., 2010).  Conditional deletion of TRF1 and 
TRF2 in murine models reveals the shelterin complex protects telomeres from ATM 
(ataxia telangiectasia mutated) and ATR (ataxia telangiectasia and Rad 3 related) 
signaling, homologous recombination, classical non-homologous end joining, 
microhomology-mediated alternative non-homologous end joining, and resection (Sfeir 
and de Lange, 2012).   
 DNA polymerases are incapable of completely replicating the linear ends of DNA 
due to the requirement of primers to initiate synthesis and the unidirectional addition of 
nucleotides, leading to the phenomenon known as the “end-replication problem” and 
erosion of telomeric DNA with each cell division (Harley et al., 1990; Levy et al., 1992).  
Human leukocytes lose approximately 25 base pairs of telomeric DNA per year, with 
reports of up to 45 bp per year (Muezzinler et al., 2013).  Normal somatic cells have a 
finite replicative capacity and enter into a senescent phase of terminal growth arrest 
once they reach their limited number of doublings (Hayflick and Moorhead, 1961).  
Telomere length acts as a mitotic clock in that once dividing cells reach a certain 
telomere length, senescence is signaled to protect from the loss of critical genes during 
replication (Allsopp and Harley, 1995; Harley et al., 1992).  Ultimately, telomere erosion 
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triggers a DNA damage response leading to growth arrest, called the M1 stage (d'Adda 
di Fagagna et al., 2003).  Cells can bypass M1 senescence in the absence of cell-cycle 
checkpoint pathways p53 and/or Rb and cells continue to proliferate until telomeres 
become critically short, resulting in crisis (M2 stage) (Wright and Shay, 1992).  Crisis is 
characterized by many uncapped chromosome ends, chromosome breakage fusion 
bridge cycles, end fusions, and mitotic catastrophe leading to apoptosis (Shay and 
Wright, 2005).  In a rare M2 cell, telomerase can become reactivated leading to 
indefinite cellular proliferation and this escaping crisis is thought to be a hallmark of 
cancer (Figure 1.5) (Hanahan and Weinberg, 2000). 
 Short, dysfunctional telomeres are a common feature of cancer cells (Maser and 
DePinho, 2002).  Telomere attrition promotes genomic instability and cancer 
development by inducing chromosome fusions and breakage (Gunes and Rudolph, 
2013).  Artandi and colleagues showed telomerase deficient, p53 mutant mice 
developed epithelial cancers through this process of breakage fusion bridge cycles 
forming complex non-reciprocal translocations and this model of telomere dysfunction 
may explain the massive ploidy changes associated with tumorigenesis (Artandi et al., 
2000).  Additional work in telomerase deficient mice and studies of human disease 
suggest telomere dysfunction plays a role in early stages of carcinogenesis (Boultwood 
et al., 1997; Chin et al., 1999; Meeker and Argani, 2004; Meeker et al., 2004; Roger et 
al., 2013; Rudolph et al., 1999; Rudolph et al., 2001; Tanaka et al., 2012).  Additionally, 
work from the Rudolph Lab provides evidence supporting the hypothesis that telomere 
dysfunction induces chromosomal instability and increases tumor initiation, but 
telomerase is needed for genome stabilization and tumor progression following initiation 
(Begus-Nahrmann et al., 2012). 
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Figure 1.5 Senescence and Crisis are Initiated by Telomere Shortening.  Telomeres 
progressively shorten with each cell division until a few short telomeres signal a growth 
arrest, known as senescence (M1).  In the absence of important cell cycle checkpoint 
pathways, cells can bypass senescence and continue dividing until telomeres become 
critically short, triggering crisis (M2).  At this point, most cells undergo apoptosis, but 
rarely cells can reactivate telomerase and become immortal.  Adapted from (Shay and 
Wright, 2010). 
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Telomerase and Cancer 
 Complete replication of telomeres is accomplished by telomerase, a specialized 
enzyme capable of reverse transcribing DNA (Blackburn, 2005). Telomerase is 
comprised of the protein hTERT, which contains a reverse transcriptase domain capable 
of catalyzing the addition of a six nucleotide repeat (TTAGGG) onto the ends of 
telomeres, and an RNA component (termed hTR), which contains a template region that 
is complementary to the human telomere sequence (Figure 1.6) (Feng et al., 1995; 
Greider and Blackburn, 1987; Morin, 1989).  Other telomere/telomerase associated 
proteins (such as TEP1, HSP90, p23, dyskerin, NOP10, NHP2, and GAR1) are required 
for assembly of a functional telomerase holoenzyme complex (Cong et al., 2002).  
Telomerase expression is low or absent in normal human somatic cells, which have a 
limited replicative capacity; however, telomerase is expressed in embryonic 
development, germ line cells, and stem cells of proliferating tissues (Chiu et al., 1996; 
Kim et al., 1994; Wright et al., 1996).  Transfection of normal somatic cells with vectors 
containing TERT can elongate telomeres and extend the lifespan of normal cells in vitro 
(Bodnar et al., 1998).  The addition of telomerase to normal cells does not cause 
tumorigenicity despite conferring cellular immortality.  To create tumorigenic cells, SV40 
large T-antigen and oncogenic H-ras are required in addition to ectopic expression of 
TERT (Hahn et al., 1999). 
 Approximately 90% of cancers have telomerase reactivation, enabling cancer 
cells to maintain their telomere length just above the critically short threshold and 
thereby avoid senescence and apoptosis and acquire indefinite replicative/proliferative 
capacity (Hanahan and Weinberg, 2011; Kim et al., 1994).  The remaining 10% of 
cancers, mainly soft tissue sarcomas and osteosarcomas, maintain telomere length 
through the alternative lengthening of telomeres (ALT) pathway (Henson et al., 2005).   
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Figure 1.6 The Telomerase Enzyme Complex.  Telomerase is comprised of hTERT, a 
protein with reverse transcriptase capability, and hTR, the RNA component of 
telomerase that contains a template region complementary to the telomere sequence 
TTAGGG.  Adapted from (Harley, 2008). 
  
hTERT
hTR 
RNA template 
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The ALT pathway is thought to rely on homologous recombination between telomeres 
and is characterized by highly heterogeneous telomere lengths and the formation of 
ALT-associated promyelocytic leukemia (PML) bodies (APB) (Nabetani and Ishikawa, 
2011).  A significant correlation has been shown between telomerase activity and tumor 
size, lymph node status, and stage in carcinomas with telomerase activity increasing as 
tumor progression occurs (Hoos et al., 1998; Looi et al., 2007; Watanabe et al., 2002).  
Additionally, increased telomerase activity is associated with increased risk of death, 
disease recurrence, and decreased disease-free survival (Clark et al., 1997; Liu, 2011). 
Interestingly, work has shown an association between HER receptors and their 
downstream signaling pathways and hTERT expression and telomerase activity.  One 
study found in cells with EGFR overexpression EGF activates the hTERT promoter 
through MAPK signaling and MEK inhibitors blocked the activation of hTERT mRNA 
expression (Maida et al., 2002).  Another group reported hTERT promoter activity was 
stimulated by HER2, Ras, and Raf via ERK-MAP-kinase dependent phosphorylation of 
the transcription factor ER81.  Futhermore, hTERT expression was increased in HER2+ 
breast cancer cell lines and tumor samples relative to HER2- counterparts (Goueli and 
Janknecht, 2004).  Moreover, the results from this study were confirmed with breast 
cancer patient samples again showing hTERT transcriptional activation in specimens 
with increased HER2 and ER81 expression (Vageli et al., 2009).  Additionally, HER2 
was found to mediate hTERT transcription through NF-κB and c-myc activation 
(Papanikolaou et al., 2011).  Furthermore, histone 3 phosphorylation by MAPK induces 
hTERT expression and telomerase activity (Ge et al., 2006).  These reports support a 
role for HER2 signaling in the induction of telomerase activity and provided the rationale 
for the work in our laboratory studying the effect of pharmacological inhibition of 
telomerase in HER2+ breast cancer cells (Goldblatt et al., 2009a). 
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Targeting Telomerase for Anti-Cancer Therapy 
 Telomerase is an attractive target for cancer therapeutics for a variety of 
reasons.  Primarily, telomerase activity is required for nearly all tumors (90% reactivate 
telomerase) to achieve limitless replicative potential.  Telomerase is encoded by non-
redundant (unique) genes, having significant therapeutic implications in that tumors are 
less likely to develop resistance to anti-telomerase therapies than other cancer targets 
that are members of a gene family (Harley, 2008).  Additionally, telomerase expression 
is absent or low in normal tissues, which generally have longer telomeres than cancer 
cells, providing a degree of tumor specificity for telomerase targeted therapeutics 
(Ouellette et al., 2011).  This differential expression between normal and cancer cells 
provide a therapeutic window in which cancer cells can efficiently be targeted by 
telomerase inhibitors while normal cells remain largely unaffected (Shay and Wright, 
2006).   
 Various strategies have been employed in targeting telomeres and telomerase.  
The most advanced anti-telomerase therapeutic is the RNA template antagonistic 
oligonucleotide imetelstat (GRN163L) and the focus of this thesis (See below) (Roth et 
al., 2010).  Telomerase enzymatic activity can also be inhibited by small molecule 
inhibitors that bind to the active site of hTERT (BIBR1532) (Ruden and Puri, 2013).  
Telomerase immunotherapy can be used to elicit cytotoxic T cell immune responses to 
kill cells expressing the hTERT peptide (GV1001 and GRN-VAC1) (Harley, 2008).  
Another approach involves using gene therapy to drive expression of a lytic virus from 
the TERT promoter leading to cell lysis (Telomelysin) (Ouellette et al., 2011).  G-
quadreplex stabilizers prevent telomerase from binding to the telomeres and uncap 
telomeres through displacement of TRF2 and POT1 (Telomestatin) (Kelland, 2007).   
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As mentioned, imetelstat is the most advanced telomerase inhibitor to date.  
Imetelstat has been studied in 17 Phase I/II clinical trials, one of which is recruiting 
pediatric patients with recurrent brain tumors and two of which were done in the 
metastatic breast cancer setting (www.clinicaltrials.gov).  Using the hTR template region 
sequence (5′-CUAACCCUACC-3′) as their target, Geron Corporation developed a thio-
phosphoramidate 13-mer oligonucleotide telomerase inhibitor, termed GRN163 (Asai et 
al., 2003).  Subsequently, addition of a 5′ terminal lipophilic (palmitoyl) group improved 
cellular uptake and enhanced potency of the telomerase inhibitor (lipid modification 
designated by an “L”, termed GRN163L) (Figure 1.7) (Herbert et al., 2005).  GRN163L, 
clinically known as imetelstat, binds with high affinity to the template region of the RNA 
component of human telomerase resulting in competitive inhibition of telomerase 
enzymatic activity by preventing telomerase from binding to and extending the telomere 
(Figure 1.8) (Gryaznov, 2010).  Our group and others have shown imetelstat alone, and 
in combination with chemotherapeutic agents including paclitaxel, doxorubicin, 
trastuzumab, and ATM kinase inhibitors or irradiation, can inhibit telomerase in a wide 
variety of tumor cells and compromise cancer cell viability and growth, both in vitro and 
in vivo (Agarwal et al., 2008; Burchett et al., 2014; Dikmen et al., 2005; Dikmen et al., 
2008; Djojosubroto et al., 2005; Goldblatt et al., 2009a; Goldblatt et al., 2009b; Gomez-
Millan et al., 2007; Hochreiter et al., 2006; Shammas et al., 2008; Tamakawa et al., 
2010).   
A potential concern of telomerase inhibition therapy is the long lag time from start 
of treatment to cell death or senescence due to their mechanism of action.  While cancer 
cells have shorter telomeres than normal cells, these cells must still undergo a large 
number of cell divisions before telomeres become critically short and signal a DNA 
damage response or growth arrest (Shay and Wright, 2006).  This suggests telomerase 
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Figure 1.7 Imetelstat Structure.  Imetelstat (GRN163L) is a telomerase template 
antagonist, consisting of a 13-mer thio-phosphoramidate oligonucleotide backbone 
covalently bound to a palmitoyl lipid moiety, which improves cellular uptake.  Adapted 
from (Gryaznov, 2010).  
Imetelstat 
Palmitoyl lipid moiety 13-mer oligonucleotide 
thio-phosphoramidate 
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Figure 1.8. Imetelstat binds telomerase RNA component  
 
 
 
 
 
 
 
 
Figure 1.8 Imetelstat Binds to the RNA Template of hTR.  Imetelstat prevents 
telomerase from binding telomeric DNA, leading to telomerase inhibition and telomere 
shortening. Adapted from (Gryaznov, 2010; Harley, 2008)  
hTERT
hTR 
Imetelstat 
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inhibitors would be most effective when used in combination with standard therapies that 
have a quick effect on tumor cells.  Combination therapy may increase drug efficacy, 
leading to critical telomere shortening, extensive tumor reduction, and lower drug doses 
helping to reduce normal cell toxicity (Ruden and Puri, 2013).  Furthermore, telomerase 
inhibitors, like imetelstat, will be best tolerated when used in combination with agents 
that have different dose-limiting toxicities, such as targeted therapies like trastuzumab 
that have very few hematological side effects.  
 
Cancer Stem Cell Hypothesis 
 The cancer stem cell (CSC) hypothesis postulates that many cancers are 
hierarchically organized and a subpopulation of cells within the tumor possess the basic 
properties of stem cells, the ability to self-renew and differentiate (Cho and Clarke, 
2008).  CSCs also have other stem cell-like properties including the active expression of 
telomerase, anti-apoptotic pathway activation, increased activity of membrane 
transporters, and an increased ability to migrate (Wicha et al., 2006).  Evidence 
suggests that CSCs may be responsible for tumor progression, metastasis, 
chemotherapy and radiotherapy resistance, and subsequent tumor recurrence (Balic et 
al., 2006; Li et al., 2008; Ponti et al., 2005; Visvader and Lindeman, 2008).  Indeed, 
breast CSCs have increased expression of proinvasive genes, increased invasion in 
vitro, and an invasiveness gene signature derived from these cells is strongly correlated 
with metastasis-free survival and overall survival (Liu et al., 2007; Sheridan et al., 2006).  
Additionally, epithelial-mesenchymal transition activation has been shown to generate 
CSCs and is associated with increased motility and acquisition of invasive and 
metastatic properties (Gupta et al., 2009; Mani et al., 2008; Morel et al., 2008).  
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Moreover, glioma stem cells are resistant to ionizing radiation due to enhanced DNA 
damage repair (Bao et al., 2006).  Hepatic cancer cells are resistant to the 
chemotherapeutic agents doxorubicin, 5-fluorouracil, and gemcitabine due to 
upregulation of ABCG2 and ABCB1 encoding efflux pumps (Haraguchi et al., 2006).  
Additionally, paired breast cancer cores pre and post neoadjuvant chemotherapy 
(docetaxel or doxorubicin and cyclophosphamide) had an increased CSC population 
following chemotherapy, showing CSCs are intrinsically resistance to conventional 
chemotherapy (Li et al., 2008).  These resistant tumorigenic cells may drive tumor 
recurrence by regenerating the bulk of the tumor following therapy (Figure 1.9) (Dontu et 
al., 2003).  This supports the need and extensive ongoing effort to find agents that target 
the CSC population.   
 Cancer stem cells were first identified in seminal work from Dr. John Dick’s 
laboratory studying Acute Myeloid Leukemia (AML).  Using methods developed to 
isolate and characterize normal hematopoietic stem cells (Baum et al., 1992; Spangrude 
et al., 1988), the authors found only a subset of cells from AML patients were able to 
recapitulate the disease in severe combined immunodeficient (SCID) recipient mice.  
These leukemia stem cells were characterized as CD34+/CD38- and had extensive 
proliferative capacity, self-renewal potential, and were able to differentiate into leukemic 
blasts in vivo (Bhatia et al., 1997; Bonnet and Dick, 1997; Lapidot et al., 1994).  Lineage 
tracing has shown a single leukemia stem cell can give rise to various populations of 
leukemic cells due to heterogeneity in self-renewal potential and these functional 
differences reflect a hierarchical arrangement of leukemia cells similar to the normal 
hematopoietic compartment (Hope et al., 2004).   
The first evidence of CSCs in solid tumors came from work in breast cancer. Al-
Hajj and colleagues identified breast CSCs from patient tumors using surface marker  
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Figure 1.9 Rationale for Targeting Cancer Stem Cells.  A)  Standard chemotherapy 
drugs target rapidly dividing cells, leading to tumor size reduction, but leaving the CSC 
population, which can drive a recurrence.  B) Targeting the CSC population leads to 
progressive tumor reduction due to exhaustion of growth potential.  C) Treating both bulk 
tumor cells and the CSCs reduces tumor size and prevents a relapse.  Adapted from  
(Dalerba et al., 2007) 
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expression and tumor regeneration potential upon mammary fat pad implantation of 
these cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice 
(Al-Hajj et al., 2003).  As few as 200 breast CSCs, defined by the phenotype 
CD44+/CD24-, were able to consistently form tumors upon transplantation, whereas 100 
fold as many (20,000) CD44+/CD24+ cells did not form any tumors.  Moreover, 
secondary and tertiary transplantation of the breast CSCs remained capable of 
generating the phenotypic heterogeneity of the initial tumor, demonstrating the self-
renewal capacity of this population as well as the ability to differentiate into bulk tumor 
cells.  Ginestier and collaborators identified another marker for breast CSCs- cells with 
high levels of aldehyde dehydrogenase 1 (ALDH1) enzymatic activity (Ginestier et al., 
2007).  ALDH1 is a detoxifying enzyme responsible for intracellular aldehyde oxidation 
and may play a role in differentiation of stem cells through oxidation of retinol into 
retinoic acid (Chute et al., 2006).  As few as 500 ALDH+ cells were able to generate 
tumors in the mammary fat pad of NOD/SCID mice and displayed CSC properties, 
notably the ability to self-renew, differentiate into ALDH- cells, and recapitulate the 
heterogeneity of the parental tumor (Ginestier et al., 2007).  Subsequently, CSCs have 
been identified and isolated in a number of other malignancies, including brain cancers, 
melanoma, ovarian cancer, prostate cancer, bone sarcomas, colon cancer, multiple 
myeloma, pancreatic cancer, and head and neck cancers (Bapat et al., 2005; Collins et 
al., 2005; Fang et al., 2005; Gibbs et al., 2005; Li et al., 2007; Matsui et al., 2004; Prince 
et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2003).  
 The expression of cell surface CSC markers is heterogeneous.  High variability in 
the CSC phenotype has been observed between patients with some tumors having few 
CSCs and in others CSCs are a substantial proportion of the tumor mass (Tirino et al., 
2013).  Moreover, tumors may harbor multiple genetically or phenotypically distinct 
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CSCs (Visvader and Lindeman, 2012).  The oncogenic events and mutations that 
contribute to transformation are thought to influence the CSC phenotype (Badve and 
Nakshatri, 2012).  This may explain why one tumor or tumor-derived cell line displays a 
certain CSC population (for example, CD44+/CD24- in MDA-MB 231 breast cancer cells) 
and another has a different CSC population (ALDH+ in SKBR3 breast cancer cells).  
Thus, a variety of markers must be used and functional assays tested when studying 
CSCs.   
Multiple studies suggest Human Epidermal Growth Factor Receptor 2 (HER2) 
plays an important role in regulating the CSC population in HER2+ breast cancer.  HER2 
overexpression and ALDH expression are significantly correlated in human breast 
cancer patient samples (Ginestier et al., 2007). The CSC population in HER2 
overexpressing breast cancer cell lines expresses the highest levels of HER2 protein 
without HER2 gene amplification changes (Magnifico et al., 2009).  Additionally, HER2 
overexpression expands the normal breast epithelial stem/early progenitor cell 
population, as well as the CSC population in malignant breast cells, resulting in 
increased tumorigenicity and invasiveness with HER2 amplification (Korkaya et al., 
2008).  HER2 blockade via trastuzumab or HER2/EGFR blockade via lapatinib 
decreases the CSC population (Korkaya et al., 2008; Magnifico et al., 2009).  
Neoadjuvant trastuzumab significantly increases pathologic complete response rate 
compared to chemotherapy alone, suggesting a reduction in the CSC population 
(Buzdar et al., 2005; Korkaya and Wicha, 2013).  Moreover, in contrast to 
chemotherapy, lapatinib reduced the CSC population in the neoadjuvant setting, 
although this decrease was not statistically significant (Li et al., 2008). 
Telomerase is expressed in both bulk cancer cells and CSCs, suggesting CSCs 
could be sensitive to telomerase inhibition therapy (Ju and Rudolph, 2006; Ponti et al., 
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2005).  Imetelstat has been shown to target the CSC population in a number of tumor 
types including glioblastoma, neuroblastoma, prostate, breast, and pancreatic cancer 
(Castelo-Branco et al., 2011; Joseph et al., 2010; Marian et al., 2010a; Marian et al., 
2010b).  While these studies investigated changes in marker expression, spheroid 
formation, and tumor growth in vivo after imetelstat treatment, the effect of telomerase 
inhibition on invasion and metastases was not addressed nor the effect of imetelstat in 
combination with standard therapies on the CSC population.  Telomerase inhibitors are 
most effective when used in combination with standard therapies, likely due to the long 
lag time to achieve telomere shortening (Ruden and Puri, 2013).  Our laboratory has 
shown that imetelstat can augment the effects of trastuzumab and restore sensitivity in 
trastuzumab-resistant breast cancer cell lines (Goldblatt et al., 2009a). 
 
Overall objective and hypothesis 
 Finding therapeutics to target the CSC population is an active area of research 
due to their role in metastasis, tumor recurrence, and resistance to conventional 
chemotherapies.  Telomerase activity is present in both the CSC and bulk populations of 
cancer cells, suggesting CSCs may be sensitive to telomerase inhibition as a potential 
therapeutic target.  Our laboratory has previously reported imetelstat can decrease lung 
metastases in a breast cancer xenograft model (Hochreiter et al., 2006), prompting us to 
question whether the decreased lung metastases were due in part to imetelstat targeting 
the CSC population.  Moreover, we have found imetelstat can augment the effects of 
trastuzumab in HER2+ breast cancers and can resensitize resistant cells to trastuzumab 
(Goldblatt et al., 2009a).  HER2 overexpression increases the CSC population, which 
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may explain the aggressive, metastatic phenotype associated with this breast cancer 
subtype. 
The goals of this project were to better understand the effect of telomerase 
inhibition on the CSC population in HER2+ breast cancer cells.  Additionally, we wanted 
to expand our studies on the effects of trastuzumab and imetelstat combination 
treatment.  This thesis specifically addresses the following hypotheses: 
1. HER2+ CSCs have active telomerase that can be inhibited by imetelstat 
treatment, leading to telomere length shortening. 
2. Imetelstat alone, and in combination with trastuzumab, can decrease the 
CSC population and their functional ability. 
3. Imetelstat, trastuzumab, and combination therapy can decrease tumor 
growth in vivo and metastases.   
To address the hypotheses presented in this thesis, a variety of cellular and 
molecular biology techniques, as well as animal model studies, were performed.  HER2+ 
breast cancer cell lines underwent Fluorescently Activated Cell Sorting to separate 
CSCs from the bulk, non-CSC population to determine telomerase activity and telomere 
length before and after imetelstat treatment in each subpopulation.  To determine the 
effect of imetelstat, trastuzumab, and combination treatment on the CSC population, 
pretreated cells underwent flow cytometry analysis of CSC marker expression.  
Mammosphere and invasion assays were used to test the functional ability of CSCs from 
HER2+ breast cancer cell lines following treatment.  Additionally, preclinical animal 
models were used to study the effect of combination treatment on tumor growth in vivo 
and to investigate the xenograft CSC population and metastasis to the lungs after 
imetelstat treatment.  
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Significance 
Despite its success, not all patients respond to trastuzumab and those that 
initially do frequently develop resistance and have disease progression within one year 
(Miller, 2004; Wu et al., 2011).  Treatment options for refractory patients are limited and 
mortality high requiring the development of suitable treatment strategies.  We expect our 
contribution here to determine whether targeting telomerase through imetelstat treatment 
in combination with trastuzumab can provide a successful treatment regimen for HER2+ 
breast cancer patients.  This research is significant because development of better 
course of therapy provides a strong clinical impact on patients with HER2+ disease.  The 
addition of imetelstat to trastuzumab may slow disease progression, delaying or possibly 
preventing patient mortality.  Moreover, this research will improve our knowledge of the 
effect of telomerase inhibitors on CSCs, specifically HER2+ CSCs, which has not been 
previously studied. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Reagents 
The telomerase template antagonist, imetelstat (GRN163L, 5ʹ-Palm-
TAGGGTTAGACAA-3ʹ), its complimentary control oligonucleotide (Sense, 5ʹ-Palm-
ATCCAATCTGTT-3ʹ), and a mismatch oligonucleotide (5′-Palm-TAGGTGTAAGCAA-3′, 
mismatched bases underlined) were kindly provided by Geron Corporation (Menlo Park, 
CA) and were prepared as previously described (Herbert et al., 2005).  Trastuzumab 
was kindly provided by the Indiana University Simon Cancer Center (IUSCC) Infusion 
Pharmacy.  All other chemicals were purchased from Sigma-Aldrich unless otherwise 
noted. 
 
Cell Culture 
HCC1569 and HCC1954 HER2+ breast cancer cell lines were purchased from 
American Type Culture Collection (ATCC CRL-2330 and CRL-2338) and cultured in 
RPMI media (Corning cellgro) containing 10% fetal bovine serum (FBS, Fisher 
Scientific).  SUM225 cells were purchased from Asterand, Inc. and were cultured in 
Ham’s F12 media supplemented with 5% FBS, 5 µg/mL insulin, and 1 µg/mL 
hydrocortisone.  SKBR3 and trastuzumab-resistant SKBR3-R pool 1 HER2+ cells were a 
generous gift from Dr. Francisco Esteva (MD Anderson Cancer Center) and were 
cultured in DMEM/F12 media containing 10% FBS.  Trastuzumab-resistant SKBR3 cells 
(SKBR3-R) were cultured with the addition of 4 µg/mL trastuzumab (Nahta and Esteva, 
2004).  TMD-231 TNBC cells were a generous gift from Dr. Harikrishna Nakshatri 
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(Indiana University School of Medicine) (Helbig et al., 2003) and were cultured in DMEM 
media containing 10% FBS.  All cells were cultured at 37°C with 5% CO2 and routinely 
checked for mycoplasma contamination.  Cells were passaged weekly and media was 
changed two-three times per week.   
 
Treatment with Imetelstat and/or Trastuzumab 
 Cells were allowed to attach overnight prior to any drug treatment.  For the 
cumulative population doubling experiments, cells were plated in triplicate in 6-well 
culture plates and media was replaced the following day with fresh media containing a 
serial dilution of imetelstat (1.25 µM, 2.5 µM, and 5 µM) or 5 µM sense oligonucleotide.  
To refresh drug, media was spiked with additional drug every 3 days and cells were 
counted and passaged every 7 days for up to 18 weeks (See Figure 2.1 for experimental 
set-up).  Population doubling was calculated as the log of the (number cells counted 
divided by number cells plated) divided by log of 2.  For the long term treatment studies 
to look at CSC marker expression, cells were plated in T75 culture flasks and media was 
replaced the following day with fresh media containing 2.5 µM imetelstat and/or 
trastuzumab [0.625 µM (1 trastuzumab: 4 imetelstat ratio) for HCC1954 and SKBR3 
cells and 0.3125 µM (1 trastuzumab: 8 imetelstat ratio) for HCC1569 cells].  Media was 
spiked with additional imetelstat every 3 days and cells were counted and passaged 
after 6 days of treatment for up to 26 weeks (See Figure 2.2 for experiment set-up).  For 
the cell sorting experiments to determine telomerase activity, cells were treated with 2.5 
µM imetelstat or sense oligonucleotide for 3 days prior to sorting.  For the cell sorting 
experiments to determine telomere length, cells were treated with 2.5 µM imetelstat or  
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Figure 2.1.  Experimental Set-up for Cumulative Population Doubling Graphs.  
Cells were plated and allowed to attach overnight.  Media was changed the next day 
with media containing varying concentrations of imetelstat or the sense oligonucleotide 
control.  Media was spiked with drug every 3 days and cells were counted and passaged 
every 7 days.   
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Figure 2.2.  Experimental Set-up for Long-term Culture.  Cells were plated and 
allowed to attach overnight.  Media was changed the next day to media containing 
imetelstat, trastuzumab, or combination.  Media was spiked with imetelstat after 3 days 
and passaged after 6 days of treatment.    
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sense oligonucleotide for 6 weeks (same experimental set-up as Figure 2.2) prior to 
sorting.  
 
Flow Cytometry and Fluorescence Activated Cell Sorting (FACS) 
Flow cytometry analysis was performed using an LSRII 407 nm laser cytometer 
(BD Biosciences) and cell sorting using a Special Order Research Product FACSAria 
sorter (BD Biosciences) through the IUSCC Flow Cytometry Core.  Cells were stained 
with APC-H7-conjugated CD44, PE-Cy7- conjugated CD24, and violet LIVE/DEAD 
fixable dead cell stain (all antibodies from BD Biosciences and viability stain from Life 
Technologies).  BD CompBeads and ArC Amine reactive compensation beads (BD 
biosciences and Life Technologies, respectively) were used to determine appropriate 
compensation.  FMO (fluorescence minus one) controls were used to determine 
appropriate gates for positive and negative populations.  The Aldefluor assay was used 
to measure and separate cells based on ALDH activity according to manufacturer’s 
guidelines (StemCell Technologies).  Control samples treated with DEAB 
(diethylaminobenzaldehyde) were used for gating the negative population.  FlowJo 
software (Tree Star) was used for all analyses. 
 
Telomerase Activity Determination 
Telomerase activity was determined using the telomeric repeat amplification 
protocol (TRAP).  The TRAP assay was performed using the TRAPeze Telomerase 
Detection kit (Millipore) and a Cy5 fluorescently labelled TS primer according to 
established protocols (Herbert et al., 2006; Wright et al., 1995).  Briefly, cells were lysed 
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in NP-40 lysis buffer (10 mM Tris-HCl, 1% NP-40, 150 mM NaCl, 0.25 mM Na 
deoxycholate, 1 mM MgCl2, 1 mM EGTA, 5 mM β-mercaptoethanol, and 10% glycerol in 
DEPC-treated H2O) at 1000 cells/µL and incubated at room temperature for 30 minutes 
with kit reagents to allow telomerase extension.  Extended products were amplified via 
PCR and run on 10% nondenaturing acrylamide gels at 200 Volts for 120 minutes.  Gels 
were visualized using a PhosphorImager.  Densitometry of the 6-bp telomerase-specific 
ladder and 36-bp internal control standard was quantified using ImageJ 
(http://imagej.nih.gov/ij).  Relative telomerase activity (RTA) was calculated as the ratio 
of the telomerase ladder to the internal control standard.    
 
Telomere Length Determination 
Average telomere length was determined using the TeloTAGGG telomere length 
assay (Roche Diagnostics) to measure terminal restriction fragments (TRF).  Genomic 
DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen) according to the 
manufacturer’s protocol.  The TeloTAGGG assay was preformed according to the 
manufacturer’s guidelines with minor changes (Roche).  Briefly, 1 µg genomic DNA was 
digested overnight using Rsa I/Hinf I restriction enzymes.  Digested DNA fragments 
were separated by electrophoresis using a 0.8% agarose gel, transferred to a nylon 
membrane (Roche) via capillary transfer and 20X SSC buffer (Invitrogen).  Following 
overnight southern transfer, DNA was UV-crosslinked to the membrane (Spectrolinker) 
and a non-radioactive DIG-labeled telomere probe was hybridized to the membrane for 6 
hours.  The blot was exposed to X-ray film for 5‒10 minutes.  Chemiluminescent 
detection of TRF’s was quantified by densitometry using ImageQuant TL (GE Healthcare 
36 
 
Life Sciences) and average telomere length was calculated using TELORUN as 
previously described (Herbert et al., 2003). 
 
Methylene Blue Cell Proliferation Assay for Combination Studies 
Cells were plated in 96 well microplates and treated for 5 days with a 1:2 serial 
dilution of imetelstat or trastuzumab.  To determine the effects of combination therapy, 
additional microplates were treated in parallel with 1:2 serial dilutions of imetelstat and 
trastuzumab, in which the two agents were at constant ratios of 1:1, 1:2, 1:4, 1:8, and 
vice versa to each other.  Cell proliferation was determined via methylene blue staining 
as previously described (Oliver et al., 1989) with minor changes.  In brief, cells were 
fixed with 100% methanol for 15 minutes, stained with 0.05% methylene blue stain 
(Ricca Chemical) for 15 minutes, washed, dried and de-stained with 0.5 M HCl.  Optical 
density readings were collected at 610 nm using an absorbent plate reader (BioTek).  
Nonlinear regression sigmoidal curves were used to determine IC50 values and 
calculated using GraphPad Prism4.  Drug interactions were quantitated using both the 
isobologram approach (Tallarida, 2011) and combination index (CI) using the Chou 
Talalay method (Chou and Talalay, 1984) calculated using CalcuSyn (BIOSOFT).  
Values that fell below the line of additivity on the isobologram are considered synergistic 
(Figure 2.3).  CI < 1 is considered synergistic; CI = 1 is considered additive; CI > 1 is 
considered antagonistic. 
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Figure 2.3.  Isobologram Method to Quantitate Drug Interactions.  IC50 values of 
drug A and B are plated on the X and Y axes.  A line is drawn to connect the 2 values, 
known as the line of additivity.  Next, the IC50 values of various combination ratios of 
drug A:B are graphed.  If the point falls below the line of additivity (blue dot above), the 
combination is synergistic.  If the point lies above the line of additivity (red dot above), 
the combination is antagonistic.   
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Mammosphere Culture Assays  
One hundred thousand pretreated cells were seeded onto ultra-low attachment 
100 mm dishes or 15,000 cells in ultra-low attachment 6-well plates for counting 
spheroids and cultured in MammoCult Medium (StemCell Technologies) supplemented 
with 4 µg/mL heparin sulfate and 0.48 µg/mL hydrocortisone .  After 7 to 10 days in 
culture, mammospheres were collected and quantified using a Z1 dual threshold Coulter 
Particle Counter (Beckman Coulter).  To generate secondary mammospheres, 
mammospheres were collected, trypisinized, replated at a density of 15,000 cells per 
well, analyzed microscopically for single cellularity, and grown under mammosphere 
conditions.   
 
Invasion Assay 
Invasive potential was determined using the Cell Invasion Assay (Millipore) per 
manufacturer’s instructions.  In brief, cells were pretreated with imetelstat, trastuzumab, 
and/or combination treatment to decrease CSC marker expression.  75,000 cells in 
serum-free media were seeded onto the top of the 24-well insert containing 8 µm pores 
and coated with ECMatrix™.  Media containing 10% FBS was placed in the bottom of 
the well.  Cells were allowed to invade for 72 hours at which point the media and cells 
that had not invaded were removed by cotton swabs.  Bottom of the inserts were 
stained, rinsed, and analyzed under light microscope.  Ten random fields per well were 
counted. 
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Western Immunoblotting 
Cells were harvested and lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 37 mM β-glycerol phosphate, 47 mM NaF, 1% NP40, 0.1% SDS, 0.5% Sodium 
deoxycholate, 10% glycerol, and protease inhibitor cocktail).  25 µg protein was loaded 
into a 10% SDS-PAGE gel and ran for 90‒120 minutes at 100 Volts.  Proteins were 
transferred to PVDF membrane at 12 Volts overnight at 4°C.  Membranes were blocked 
for 60 minutes in 5% instant nonfat dry milk in PBS-T.  HER2 antibody (Calbiochem) was 
used at 1:1000 in 5% milk in PBS-T and 1:10,000 secondary antibody (goat anti-mouse, 
Pierce).  ALDH antibody (BD biosciences) was used at 1:1000 in 5% milk in PBS-T and 
1:3000 secondary antibody.  Beta-actin antibody (Sigma) served as a loading control 
and was used at 1:1000 in 5% milk in PBS-T and 1:10,000 secondary antibody.  Primary 
antibodies were incubated overnight at 4°C and secondary antibodies were incubated for 
60‒75 minutes at room temperature.   
 
Xenograft mice studies 
All animal experiments were approved and carried out in strict accordance by the 
Institutional Animal Care and Utilization Committee (Study number 3715 and 10711) at 
the Indiana University School of Medicine.  750,000 Xenograft HCC 1954 (1:1 mixture of 
serum-free media and Matrigel® (BD Biosciences)) or 1 million TMD-231 (in serum free 
media) cells were implanted into the mammary fat pad of 5‒7 week old female 
NOD/LtSz-scid IL2Rgamma-null (NSG) mice.  Surgery was performed under isoflurane 
anesthesia and 0.05 mg/kg buprenorphine was given for pain management.  Animals 
were treated with saline vehicle (thrice weekly), trastuzumab (20 mg/kg, twice weekly), 
and/or imetelstat (30 mg/kg, thrice weekly) by intraperitoneal injection.   Tumor volume  
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Figure 2.4.  Xenograft HCC1954 Animal Study Set-up.  Forty NSG mice underwent 
mammary fat pad injection surgery and were divided equally into 4 treatment groups-
vehicle control, imetelstat, trastuzumab, and combination.  Imetelstat was administered 
by intraperitoneal injection three times per week; trastuzumab was also administered by 
intraperitoneal injection twice weekly.  Animals were weighed once a week and tumor 
volume was measured by calipers twice weekly.  Animals were sacrificed after 10 weeks 
of treatment.     
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Figure 2.5.  TMD-231 Animal Study Set-up.  Fourteen NSG mice underwent mammary 
fat pad injection surgery and were divided equally into 2 groups-vehicle control (saline) 
and imetelstat.  Imetelstat was administered by intraperitoneal injection three times per 
week.  Animals were weighed once a week and tumor volume was measured by calipers 
twice weekly.  Animals were sacrificed after 7 weeks of treatment.   
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was calculated as (length x width2) / 2 (in mm) by caliper measurements twice weekly.  
See Figures 2.4 and 2.5 for experimental set-up.  After 7 weeks for TMD-231 and 10 
weeks for HCC 1954, animals were euthanized and lungs and primary tumor were 
resected.  Lungs were formalin fixed, paraffin embedded, sectioned, and stained with 
hematoxylin and eosin (H&E) for analysis.  Primary tumor tissue was mechanically and 
enzymatically digested with collagenase/hyaluronidase solution (StemCell 
Technologies), incubated for 2 hours, and passed through a 40 µm cell strainer to 
ensure single cellularity prior to cell culture or flow cytometry analysis. 
 
Statistical Analysis 
GraphPad Prism4 (GraphPad Software, Inc.) was used to complete all statistical 
analyses.  Student’s t-test, one-way ANOVA with Tukey’s multiple comparisons post-
tests, and two-way repeated measures ANOVA with Bonferroni post-tests were used to 
determine p-values.  In all experiments, p < 0.05 was considered statistically significant. 
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CHAPTER THREE 
RESULTS 
 
Long-term Treatment with Imetelstat Inhibits Cell Growth and Telomerase Activity 
in HER2+ Breast Cancer Cell Lines 
 We utilized a panel of six breast cancer cell lines, five of which are reported to 
have HER2 protein overexpression and the other is triple negative (ER-, PR-, HER2-), for 
the experiments conducted in these studies (Table 3.1)(Neve et al., 2006).  To verify 
HER2 protein is overexpressed in these cell lines, we performed Western blot analysis.  
We found HER2 is indeed overexpressed in the HCC1569, HCC1954, SKBR3, SKBR3-
R, SUM225, BT474, BT474-R, and MCF7 HER2 cell lines and HER2 expression is low 
in the TMD-231, MCF7 pcDNA, and HCC1937 breast cancer cell lines (Figure 3.1).  We 
chose to focus our work mainly on the HCC1569 and HCC1954 cell lines, as these lines 
are ER- (response rates to anti-HER2 therapy vary depending on ER status (Nahta and 
O'Regan, 2012)) and have not previously been studied with telomerase inhibitors.  We 
also included work on the SKBR3, SKBR3-R, and TMD-231 cells, which are also ER- but 
our laboratory has investigated the use of telomerase inhibition in these cell lines 
previously.   
To study the effects of imetelstat treatment in HER2+ breast cancer cell lines, 
cumulative population doublings were measured in two HER2+ cell lines not previously 
studied for telomerase inhibition, HCC1569 and HCC1954.  Imetelstat treatment 
inhibited proliferation in both cell lines as measured by cumulative population doublings 
(Figure 3.2).  Cumulative population doublings of the HCC1569 cell line statistically 
significantly differed between imetelstat and untreated cells after 35, 42, and 63 days of 
treatment for 5 µM, 2.5 µM, and 1.25 µM imetelstat, respectively, and remained different 
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Figure 3.1.  Certain Breast Cancer Cell Lines Overexpress HER2 Protein.  
Western blot analysis of various breast cancer cell lines shows HCC1954, 
HCC1569, SUM225, SKBR3, BT474, BT474-R (HR5), MCF7-HER2, SKBR3, 
and SKBR3-R cell lines overexpress HER2 protein, as previously reported.   
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Figure 3.2.  Long-term Treatment with Imetelstat Inhibits Cellular Proliferation.  
Cumulative Population doubling graphs of HCC1569 (A) and HCC1954 (B) cell lines. 
UT= untreated, 163L= imetelstat   
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throughout the remainder of the experiment (Figure 3.2 A, two-way repeated measures 
ANOVA, p < 0.05).  HCC1569 cells stopped doubling and reached the stationary phase 
or plateau of the population doubling graph after 17 weeks of treatment.  Cumulative 
population doublings of the HCC1954 cell line statistically significantly differed between 
imetelstat and untreated cells after 56, 63, and 71 days of treatment for 5 µM, 2.5 µM, 
and 1.25 µM imetelstat, respectively, and remained different throughout the remainder of 
the experiment (Figure 3.2 B, two-way repeated measures ANOVA, p < 0.05).  
HCC1954 reached the stationary phase after 10 weeks of treatment.  The sense 
oligonucleotide control had a minor effect on cell proliferation, which is likely an 
unrelated oligonucleotide effect, but it occurred much later than imetelstat and did not 
inhibit cells from continuing to proliferate.  Although cumulative population doublings 
began to significantly differ sooner in the HCC1569 cells, it took longer to reach the 
plateau than in HCC1954 cells.  The HCC1569 cells were slower growing, doubling 
about 4 times per week versus 5 times in the HCC1954 cells, and have longer baseline 
telomere length, which may explain why a longer treatment regimen is required to reach 
the stationary phase in this cell line.  We also measured telomerase activity during long-
term treatment with imetelstat by the TRAP assay.  As expected, imetelstat was able to 
inhibit telomerase activity for all time points studied (up to 6 weeks of treatment) with the 
control sense oligonucleotide having no effect on telomerase activity (Figures 3.3), 
suggesting cells remained sensitive to telomerase inhibition and did not become 
resistant to imetelstat treatment.   
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Figure 3.3.  Continued Treatment with Imetelstat Inhibits Telomerase Activity.  
TRAP assay to determine telomerase activity of A) HCC1569 and B) HCC1954 cells 
continually treated with 2.5 µM imetelstat or sense control for up to 6 week, telomerase 
activity determined weekly.  LB= lysis buffer, UT= untreated, 163L= imetelstat 
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HER2+ CSCs Have Active Telomerase and Are Sensitive to Telomerase 
Inhibition via Imetelstat  
Previous studies have reported similar telomerase activity between CSCs and 
their bulk tumor cell counterparts, as well as similarities in telomere length (Joseph et al., 
2010; Ponti et al., 2005).  We wanted to determine whether our HER2+ cell lines also 
had similar telomerase activity and telomere length in the CSC, non-CSC (bulk tumor 
cells), and unsorted populations.  HCC1569 cell line was flow sorted based on 
CD44/CD24 expression and ALDH enzymatic activity.  ALDH enzymatic activity was 
used to sort the SKBR3 and HCC1954 cell lines.  See Figure 3.4 for representative 
sorting gates used in these experiments.  Unsorted, non-CSC, and CSC populations all 
had active telomerase, as visualized by the robust ladder formation of telomerase 
products in the TRAP assay (Figure 3.5 A, C) and relative telomerase activity 
quantification (Figure 3.5 B, D).  There was no difference in relative telomerase activity 
between CSC, non-CSC, and unsorted cells in the HCC1569 cell line based on 
CD44/CD24 expression (one-way ANOVA, p > 0.05).  All other samples were only 
sorted twice so statistical analysis could not be performed.  We also tested whether 
imetelstat can inhibit telomerase activity in the different subpopulations.  Imetelstat 
(labelled 163L) was able to abolish telomerase activity in both the CSC and non-CSC 
populations; again, the sense oligonucleotide control did not affect telomerase activity 
(Figure 3.5 A‒D).   
In line with the previous reports, we found similar average telomere length 
between the CSC and non-CSC populations in our HER2+ breast cancer cell lines 
(Figure 3.6).  Six weeks of imetelstat treatment decreased average telomere length in 
the HCC1954 cell line, but not the HCC1569 cell line (Figure 3.6 B).  HCC1569 cells had 
a longer baseline telomere length than HCC1954, possibly explaining why we did not  
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Figure 3.4.  Flow Sorting Gating Strategy.    A) HCC1569 cells were sorted based on 
CD44/CD24 expression into CSC and non-CSC populations.  B) SKBR3, HCC1954, and 
HCC1569 cells were sorted based on ALDH activity.  Aliquots were also incubated with 
ALDH inhibitor diethylamino benzaldehyde (DEAB) to gate ALDH- (non-CSC) and 
ALDH+ (CSC) populations.  
A 
B 
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Figure 3.5.  CSCS Have Active Telomerase That Can Be Inhibited by Imetelstat.   
A) Detection of telomerase activity by TRAP assay of HCC1569 flow sorted CSCs and 
non-CSCs by marker expression following 3 day treatment of 2.5 µM imetelstat or sense 
oligonucleotide.  B) Average quantification of relative telomerase activity from 
representative image A) and 1-2 additional experiments using ratio of telomerase 
products to internal standard.  Standard deviation bars in CD44/CD24 samples, as this 
was repeated 3 times with no significant difference.  C) TRAP assay of SKBR3 and 
HCC1954 flow sorted CSCs and non-CSCs following 3 day treatment of 2.5 µM 
imetelstat or sense oligonucleotide. D) Average quantification of relative telomerase 
activity from representative image C) and 1 additional experiment.  UT= untreated cells, 
163L= imetelstat treated cells 
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Figure 3.6.  Average Telomere Length is Similar in all Subpopulations with 
Imetelstat Treatment Leading to Telomere Shortening.  A)Telomere length 
determination by Terminal restriction fragment analysis of HCC1569 and HCC1954 flow 
sorted cells following 6 weeks of treatment of 2.5 µM imetelstat or sense oligonucleotide.  
MWM= molecular weight marker, Unsort= unsorted cells, S= sense oligonucleotide 
control, HCC1569 CSC= CD44+/CD24-, HCC1569 non-CSC= CD44+/CD24+, HCC1954 
CSC= ALDH+, HCC1954 non-CSC= ALDH- .   B) Average telomere length quantified 
using TELORUN. Kb=kilobase  
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see differences in average telomere length at this time point of treatment.  However, 
there appeared to be a shortening of the longer telomeres in both cell lines with 
imetelstat treatment, shown by a shift down in the telomere smear on the membrane 
(Figure 3.6 A).  Indeed, examination of the densitometry of the telomere smears 
revealed shortening of longer telomeres in both cell lines with imetelstat treatment, 
shown by a shift in the curve toward a smaller molecular weight (Figure 3.7).  The longer 
baseline telomere length of HCC1569 may also explain why longer treatment duration is 
needed to achieve the stationary phase or plateau of the population doubling graph 
(Figure 3.2).  Due to the fact the TRF analysis determined average telomere length, we 
cannot rule out the possibility of a few short telomeres in the CSC population or cells 
after treatment with imetelstat. 
 
Telomerase Inhibition Can Decrease CSCs and Limit Mammosphere Formation 
 The use of breast cancer cell lines to study CSCs has been validated (Charafe-
Jauffret et al., 2009; Fillmore and Kuperwasser, 2008).  HCC1569, HCC1954, SKBR3, 
SUM225, and TMD-231 cell lines were subjected to flow cytometry analysis of CD44 and 
CD24 marker expression, as well as ALDH enzymatic activity.  The HCC1569 cell line 
was positive for CD44 expression and contained both positive and negative CD24 
expressing cells, allowing us to use this cell line to measure the CD44+/CD24- CSC 
population (Figure 3.8 A).  Additionally, TMD-231 cells stained almost entirely 
CD44+/CD24-, but did not exhibit ALDH enzymatic activity (Figure 3.8 E).  HCC1954, 
SKBR3, and SUM225 cell lines did not have a measureable CD44+/CD24- population 
(Figure 3.8 B‒D).  As predicted by the correlation of HER2 and ALDH, HCC1569, 
HCC1954, and SKBR3 cells had ALDH+ CSC subpopulations (Figure 3.8 A‒C)  
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Figure 3.7.  Longer Telomeres are Shortened with Imetelstat Treament.  Telomere 
length quantification using TELORUN of sorted HCC1569 (A-B) and HCC1954 (C-D) 
cells pretreated with imetelstat or untreated for 6 weeks prior to sorting CSC (top panels) 
and non-CSC (bottom panels) populations.  Shift in Molecular Weight (telomere length in 
Kb) after imetelstat treatment (red lines) shows telomere shortening of the longer 
telomeres within each sample.  a.u. = arbitrary units   
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Figure 3.8.  Cell Lines have Variable CSC Marker Expression. Flow cytometry 
analysis of CD44/CD24 (left panels) and ALDH enzymatic activity (right panels) of 
HCC1569 (A), HCC1954 (B), and SKBR3 (C), SUM225 (D), and TMD-231 (E) cell lines.  
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(Ginestier et al., 2007).  We were not able to detect substantial ALDH enzymatic activity 
in the HER2+ SUM225 cell line despite this cell line had the highest protein expression of 
ALDH (Figure 3.9), suggesting protein expression does not predict enzymatic activity.   
 To determine the effect of telomerase inhibition on the CSC population, we 
measured CD44+/CD24- expression in the HCC1569 cell line with and without imetelstat 
treatment.  Imetelstat decreased the CSC population by more than 25% (62.9% in 
imetelstat treated versus 88.7% in untreated, 1.41 fold decrease), whereas the sense 
oligonucleotide control had no effect (Figure 3.10).  Furthermore, imetelstat pretreatment 
statistically significantly decreased mammosphere count, an in vitro assessment of stem 
cell function, compared to untreated and sense controls (Figure 3.11 B‒C).  Spheroids 
also appeared smaller after imetelstat pretreatment (Figure 3.11 A), suggesting 
imetelstat inhibited proliferation of the CSCs.  
 Additionally, we wanted to follow-up on our previous work showing imetelstat 
decreased lung metastases in vivo by using the same cell line as that study (Hochreiter 
et al., 2006).  In a pilot experiment, imetelstat decreased the CSC population of the 
TNBC cell line TMD-231 by 1.45 fold (98.7% in the untreated vs 68.3% with imetelstat 
treatment), whereas the mismatch oligonucleotide had no effect (Figure 3.12), 
suggesting imetelstat can target the CSC population of other breast cancer subtypes as 
well.  Moreover, imetelstat decreased the functional ability of these CSCs, as shown by 
decreased spheroid formation efficiency, 9.36% in the untreated vs 1.5% with imetelstat 
pretreatment (Figure 3.13).  Furthermore, imetelstat inhibited telomerase activity in both 
adherent and mammosphere cultures in this experiment (Figure 3.14), indicating 
imetelstat is able to infiltrate a mass of cells similar to tumors in patients.  
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Figure 3.9.  Cell Lines have Variable ALDH1 Protein Expression.  Western 
immunoblotting for ALDH1 protein expression from HCC1937, HCC1954, HCC1569, 
Sum225, and SKBR3 cell lines. 
 
 
  
58 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.  Imetelstat, but not the Sense Oligonucleotide Control, Decreases the 
Percentage of CSCs.  A) Representative flow cytometry analysis of CSC marker 
expression of HCC1569 cells following imetelstat or sense treatment. B) Average 
percent CSC (n=2) after 144 days of treatment.   
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Figure 3.11.  Imetelstat Inhibits Mammosphere Formation.  A) Representative 
images of primary mammosphere cultures from HCC1569 cells pretreated for 150 days 
and cultured for 8 days as mammospheres without additional treatment, 4X 
Magnification, 200 µm scale bar.  B) Primary mammosphere count grouped by 
mammosphere size (n=3), average ± SD, one-way ANOVA, * p<0.05, ** p< 0.01 
compared to untreated.   C) Sum of mammosphere size groups graphed as total 
mammosphere count, average ± SD, one-way ANOVA, * p< 0.05 compared to 
untreated. 
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Figure 3.12.  Imetelstat Decreases the Percentage of CSCs in the TNBC Cell Line 
TMD-231.  A)  Flow cytometry analysis of TMD-231 cells treated with 2.5 µM imetelstat 
or mismatch control oligonucleotide for 56 days.  B) Bar graph of %CD44+/CD24- CSC 
population following 56 days of treatment, n=1.  
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Figure 3.13.  Imetelstat Inhibits Mammosphere Formation in TMD-231 Cells.   
A) Representative images of primary mammosphere cultures from TMD-231 cells 
pretreated for 98 days and cultured as mammospheres for 7 days without additional 
treatment, 10X Magnification, 400 µm scale bar.  B) Graph of Spheroid formation 
efficiency (Mammosphere count/ number plated), n=1. 
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Figure 3.14.  Imetelstat Inhibits Telomerase Activity in Both Adherent and 
Spheroid TMD-231 Cell Cultures.  A) Telomerase activity as determined by the TRAP 
assay for TMD-231 cells cultured as adherent monolayers or non-adherent spheroids 
and treated with 2.5 µM imetelstat or mismatch control oligonucleotide for 6 or 7 weeks.  
B) Quantification of A) and graphed as percent telomerase activity relative to the 
untreated. 
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Imetelstat Augments the Effects of Trastuzumab in HER2+ Breast Cancer Cell 
Lines  
 Our laboratory has previously reported a synergistic effect of imetelstat and 
trastuzumab combination therapy in vitro (Goldblatt et al., 2009a).  Moreover, we also 
found imetelstat is able to resensitize trastuzumab-resistant cells to trastuzumab.  We 
next wanted to verify this effect also applied to the HCC1569 and HCC1954 cell lines.  
The HCC1569 and HCC1954 cell lines have previously been classified as having a de 
novo resistance to trastuzumab, due to not decreasing cell growth rate by greater than 
1.2 fold and soft agar colony formation by greater than 20% at a concentration of 15 
µg/mL (approximately 103 nM) (O'Brien et al., 2010).  Nonetheless, IC50 values, the drug 
concentration needed to inhibit 50% of cellular proliferation, of trastuzumab and 
imetelstat were determined for both HCC1569 and HCC1954 cell lines.  The ratio used 
in combination experiments was determined by dividing the IC50 value of imetelstat by 
the IC50 value of trastuzumab; therefore we treated HCC1569 cells with a 1:8 ratio of 
trastuzumab to imetelstat and HCC1954 cells with a 1:4 ratio of trastuzumab to 
imetelstat.  In the HCC1569 cells, the combination decreased the concentration of both 
drugs needed to achieve the IC50 (Figure 3.15).  Moreover, the combination index 
showed a synergistic effect (CI < 1) of combination treatment at most concentrations 
tested (Table 3.2).  Similarly, the combination in HCC1954 cells decreased the 
concentration of both drugs needed to achieve the IC50 (Figure 3.16).  Likewise, the 
combination index showed a synergistic effect at most combination treatment 
concentrations studied (Table 3.3).  Moreover, we tested different drug ratios in the 
HCC1954 cell line and found all ratios fell below the line of additivity on the isobologram, 
although 1:2 and 2:1 ratios (trastuzumab : imetelstat) may not be statistically below the 
line of additivity (Figure 3.16 C).  Although these cells are reported to be innately  
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Figure 3.15.  Imetelstat Augments the Effects of Trastuzumab in HCC1569 Cells.  
A) Representative dose-response curve of trastuzumab, imetelstat, and 1:8 combination 
treatment in HCC1569 cells.  B) Average IC50 value of each drug individually and in 
combination.  n=3 experiments with 16‒24 replicates each. 
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Figure 3.16.  Imetelstat Augments the Effects of Trastuzumab in HCC1954 Cells. 
A) Representative dose-response curve of trastuzumab, imetelstat, and 1:4 combination 
treatment in HCC1954 cells.  B) Average IC50 value of each drug individually and in 
combination.  n=3 experiments with 8‒24 replicates each.  C) Isobologram of HCC1954 
cells treated with varying ratios of trastuzumab : imetelstat.  Average IC50 values are 
graphed.  n=3 experiments with 6 replicates each.    
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resistant to trastuzumab and we did notice little effect on cell proliferation at lower 
concentrations, we were able to determine IC50 values for trastuzumab and showed the 
combination treatment decreased the IC50 value for both trastuzumab and imetelstat.  
These combination studies suggest imetelstat can augment the effects of trastuzumab.   
 
Imetelstat in Combination with Trastuzumab Decreases the CSC Population  
As imetelstat is used in combination with standard of care treatments like 
trastuzumab, we next wanted to determine the effect of imetelstat and trastuzumab 
combination treatment on the CSC population.  For these combination studies, we used 
2.5 µM imetelstat, as this concentration is clinically relevant to the dose received by 
patients, and either 312.5 nM or 625 nM trastuzumab for the 1:8 or 1:4 ratio, 
respectively, used in our drug interaction studies above.  Combination treatment 
statistically significantly decreased the CD44+/CD24- CSC population in the HCC1569 
cell line (p < 0.05 for 12‒54 days of treatment) by approximately 25% or a 1.36 fold 
decrease (Figure 3.17).  However, addition of trastuzumab had no effect on the 
percentage of CD44+/CD24- CSCs (p > 0.05 for all time points).   
Additionally, we determined the percentage of ALDH+ CSCs in the HCC1569, 
HCC1954, SKBR3, and SKBR3-R cells.  As ALDH+ cells are determined by enzymatic 
activity (the removal of a hydrogen group on an aldehyde substrate), there is greater 
variability between samples than measuring surface marker expression for CD44 and 
CD24, which makes determining statistically significant differences difficult because the 
standard deviation is so large.  In the HCC1569 cell line, imetelstat and combination 
treatment decreased the ALDH+ CSC population up to 80%, with a statistically significant 
decrease at 6, 18, and 24 days of treatment (Figure 3.18).  In the HCC1954 cell line,  
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Figure 3.17.  Imetelstat Alone and in Combination with Trastuzumab Decreases 
the CD44+/CD24- CSC Population.  CSC marker expression analyzed by flow 
cytometry.  Average percent CD44+/CD24- ± SD, n=3, one-way ANOVA, * p < 0.05, ** p 
< 0.01, *** p < 0.001 
   
70 
 
 
 
 
 
 
 
Figure 3.18.  Trastuzumab, Imetelstat, and Combination Treatment Decrease the 
ALDH+ CSC Population in HCC1569 Cells.  A) ALDH enzymatic activity measured by 
flow cytometry.  Average percent ALDH+ ± SD when error bars are shown, n=2‒3, one-
way ANOVA, * p < 0.05, ** p < 0.01.  B) Representative ALDH enzymatic activity from 
one experiment. 
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trastuzumab, imetelstat, and combination treatment decreased the ALDH+ CSC 
population by more than 50% when only one experiment is analyzed; however, there 
was no difference statistically due to the high variability in enzymatic activity when you 
analyze all three experiments together (Figure 3.19).  Furthermore, in the SKBR3 cell 
line, trastuzumab, imetelstat, and combination treatment again decreased the ALDH+ 
CSC population by up to 60% (Figure 3.20), although the treatments did not decrease 
the CSC population at every time point and again there was no difference statistically 
when you analyze all three experiments together due to the enzymatic activity variability.  
Additionally, we looked at the SKBR3-R cell line, which has an acquired resistance to 
trastuzumab due to continuous exposure to trastuzumab in cell culture (Nahta and 
Esteva, 2004).  Indeed, 0.625 µM trastuzumab decreased cellular proliferation in the 
SKBR3 cell line, but not the SKBR3-R cell line (Figure 3.21). In the SKBR3-R cells, 
imetelstat decreased the ALDH+ CSC population at every time point and up to 60%, 
while trastuzumab and combination treatment decreased the CSC population at only half 
the time points when looking at one experiment (Figure 3.22).  Interestingly, the time 
points with increased CSCs after trastuzumab treatment also had increased CSCs after 
combination treatment (Figure 3.22 B).  In accordance with previous reports that showed 
trastuzumab decreased the percentage of ALDH+ CSCs after 2-5 days of treatment, we 
also observed a decrease in the ALDH+ CSC population after 6 days of trastuzumab 
treatment in all 4 cell lines (Korkaya et al., 2008).  These results suggest imetelstat 
alone, and in combination with trastuzumab, is able to target the CSC population.  
Notably, in the HCC1569 cell line, combination treatment decreased both CD44+/CD24- 
and ALDH+ CSCs (Figures 3.17 and 3.18). 
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Figure 3.19.  Trastuzumab, Imetelstat, and Combination Treatment Decrease the 
ALDH+ CSC Population in HCC1954 Cells.  A) ALDH enzymatic activity measured by 
flow cytometry.  Average percent ALDH+ ± SD, n=3.  B) Representative ALDH enzymatic 
activity from one experiment.  
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Figure 3.20.  Trastuzumab, Imetelstat, and Combination Treatment Decrease the 
ALDH+ CSC Population in SKBR3 Cells.  A) ALDH enzymatic activity measured by 
flow cytometry.  Average percent ALDH+ ± SD, n=3.  B) Representative ALDH enzymatic 
activity from one experiment. 
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Figure 3.21.  Trastuzumab Limits Cellular Proliferation in SKBR3 Cells, But Not 
SKBR3-R Cells.  Cumulative population doubling graphs for A) SKBR3 and B) SKBR3-
R cells.   
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Figure 3.22.  Trastuzumab, Imetelstat, and Combination Treatment Decrease the 
ALDH+ CSC Population in SKBR3-R Cells.  A) ALDH enzymatic activity measured by 
flow cytometry.  Average percent ALDH+ ± SD, n=3.  B) Representative ALDH enzymatic 
activity from one experiment.  
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Imetelstat in Combination with Trastuzumab Inhibits Self-renewal and Invasive 
Potential of CSCs 
We next wanted to determine if the decrease in the CSC population after 
imetelstat and combination treatment resulted in decreased functional ability of the 
CSCs.  Pretreated cells were plated in non-adherent dishes using undifferentiating 
medium.  Under these culture conditions, cells with self-renewal potential grow to form 
spheroids called mammospheres.  We observed a significant decrease in 
mammosphere count following trastuzumab, imetelstat, and combination treatment after 
short term pretreatment (12 and 36 days) and long term pretreatment (90 days), 
suggesting CSC self-renewal is continually inhibited by these agents (Figure 3.23).  
Moreover, short term treatment with imetelstat does not lead to telomere shortening, but 
long term treatment does, suggesting imetelstat inhibits self-renewal potential of CSCs in 
telomere length dependent and independent mechanisms. 
It has been reported that the CSC population has an increased invasive potential, 
an early step required for metastasis (Charafe-Jauffret et al., 2009; Sheridan et al., 
2006).  We performed in vitro invasion assays to determine if the decrease in CSCs 
following twelve days of imetelstat and/or trastuzumab treatment could also decrease 
invasive potential.  While the invasive potential for the HER2+ cell lines is much lower 
than other breast cancer cell lines, such as MDA-MD-231, we extended the length of the 
experiment (72 hours instead of 24 hours reported in other breast cancer cell lines) and 
were able to see some cells had invaded through the basement membrane and onto the 
bottom of the membrane insert (Neve et al., 2006).  Ten random fields per well were 
counted.  Imetelstat and combination treatment significantly decreased the invasive 
potential compared to untreated samples, with less than half as many cells invading in 
those treatment groups (Figure 3.24).  These results suggest the decrease in CSCs  
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Figure 3.23.  Trastuzumab, Imetelstat, and Combination Treatment Inhibit 
Mammosphere Formation of HCC1569 Cells. A) Representative Images of Primary 
Mammospheres cultured from HCC1569 cells.  4X Magnification, 200 µm scale bar.  B) 
Total mammosphere counts from 3 different pretreatment time points, Average ± SD, 
n=3, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001.   
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Figure 3.24.  Imetelstat Alone and in Combination with Trastuzumab Limits 
Invasion Potential of HCC1569 Cells.  A) Representative images of invaded cells in 
purple, 10X magnification, 60 µm scale bar.  B) Invaded cells in 10 random fields per 
well, Average ± SD, n=3, one-way ANOVA, ** p < 0.01.  
A 
B 
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following imetelstat and combination treatment also inhibits the functional ability of the 
CSCs, shown by decreased self-renewal and invasive potentials.   
 
Imetelstat and Trastuzumab Combination Treatment Decreases Primary Tumor 
Growth In Vivo 
 We and others have shown imetelstat treatment can decrease primary tumor 
growth in xenograft mouse models (Dikmen et al., 2005; Goldblatt et al., 2009b; 
Hochreiter et al., 2006; Shammas et al., 2008).  However, the effect of imetelstat and 
trastuzumab combination treatment on xenograft tumor growth has not previously been 
studied.  We chose to use the HCC1954 cell line for our animal model studies because 
these cells are ER-; therefore, addition of an estrogen pellet is not required and tumor 
formation via mammary fat pad inoculation has previously been reported  
(Korkaya et al., 2008).  Initially, HCC1954 cells only formed tumors when injected 
subcutaneously and no tumor formation was observed after inoculation in the mammary 
fat pad of female, 5‒7 week old NSG mice.  We resected these subcutaneous tumors, 
mechanically digested them, and grew them as a monolayer culture.  The xenograft 
HCC1954 cells, the cells that grew in culture from the xenograft tumors, are 
morphologically similar to the parental HCC1954 cells (Figure 3.25) and have 
overexpressed HER2 protein as shown by immunofluorescence (Figure 3.26), indicating 
our xenograft cell line was derived from the inoculated HCC1954 cells and not from 
murine cells.  In a two animal pilot study, the xenograft HCC1954 cells were able to form 
tumors after mammary fat pad implantation in both mice and appeared to be forming 
metastatic lesions in the lungs as analyzed by H&E staining of lung tissue slides by a 
pathologist.  Three to seven very small lesions of less than ten cells each were found in  
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Figure 3.25.  Xenograft HCC1954 Cells have Similar Morphology to Parental Cell 
Line.  Xenograft mouse tumors were resected, digested, and grown as monolayer cells.  
Representative images of parental HCC1954 and xenograft HCC1954 cultures, 4X 
magnification, 200 µm scale bar.    
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Figure 3.26.  Xenograft HCC1954 Cells Overexpress HER2 Protein. 
Immunofluorescence staining of Parental and Xenograft HCC1954 cells showing HER2 
protein (red) is overexpressed in both cell lines, DAPI (blue) used as a nuclear stain, 
secondary antibody (AB) used as negative control for background staining, 20X 
magnification.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
the lung tissue of both mice (summarized in Table 3.4 and Figure 3.27).  It was 
recommended to extend our study for an additional week or two to allow the metastases 
to grow larger.  Therefore, in our study, we chose to inject 750,000 cells instead of 
1,000,000 cells, hoping we would be able to lengthen the study without the tumor burden 
hindering the well-being of the animals.   
In our experimental study, we implanted 750,000 xenograft HCC1954 cells into 
the fourth mammary fat pad of female, 5‒7 week old NSG mice and began treating with 
PBS (thrice weekly), imetelstat (thrice weekly), and/or trastuzumab (twice weekly) four 
days after the minor surgery.  Trastuzumab and combination treatment delayed the 
onset of tumor formation and inhibited tumor growth (Figure 3.28 A).  We found a 
significant decrease in primary tumor volume in the trastuzumab and combination 
treatment groups compared to the saline vehicle control group (p < 0.01) (Figure 3.28 B).  
However, the study was concluded, due to burdensome tumor volume in the vehicle 
control group, before differences in tumor volume between the trastuzumab alone and 
combination group could be observed.  The effects on tumor growth in the imetelstat 
only group lie between saline control and trastuzumab/combination groups.  Final tumor 
volume was not statistically significantly different between saline control and imetelstat 
(p > 0.05), as well as imetelstat and trastuzumab or combination (p > 0.05 for both).   
We determined tumor growth rates, calculated as the slope of the line of tumor 
volume versus days post inoculation, as an additional means of looking at tumor volume 
differences in our four sample groups (Figure 3.29).  Tumor growth rates roughly 
doubled from combination to trastuzumab alone (6.0314 and 12.909, respectively).  
Tumor growth rates more than doubled between trastuzumab and imetelstat (12.909 and 
30.94, respectively), but importantly saline control tumor growth rate was more than  
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Figure 3.27.  Xenograft HCC1954 Cells Metastasize to the Lungs.  Xenograft 
HCC1954 cells formed tumors after implantation in the mammary fat pad of NSG mice 
and were able to colonize small metastatic lesions (less than 10 cells each) in the lungs.  
An additional passage in mice (Secondary Xenograft Cell Line) was potentially able to 
form metastases in the lungs, but these mice had to be sacrificed early due to tumor 
burden.   
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Figure 3.28.  Trastuzumab and Combination Treatment Inhibits Xenograft 
HCC1954 Primary Tumor Growth.  A) Tumor Volume (length x width2/2) was 
determined by caliper measurements twice weekly and graphed throughout the study.  
Average ± SEM, n=9‒10 animals per group.  B) Final Tumor volume for each sample 
group.  Average + SD, n=9‒10 animals per group, one-way ANOVA with Tukey’s post-
tests, ** p < 0.01.  
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Figure 3.29.  Imetelstat, Trastuzumab, and Combination Treatment Decreases 
Xenograft HCC1954 Tumor Growth Rates.  A) Linear Regression was used to 
determine tumor growth rate (slope of the line, tumor volume per days post inoculation) 
for each sample group.  B) Bar graph displaying Rate of Tumor Growth, as calculated in 
A) for each sample group. 
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double that of imetelstat (68.544 versus 30.94), suggesting imetelstat somewhat inhibits 
tumor growth by itself but not to the extent of trastuzumab or combination treatment.  
Different tumor growth rates between combination and trastuzumab alone groups 
suggest addition of imetelstat to trastuzumab can enhance the inhibitory effect of 
trastuzumab on tumor growth, supporting our in vitro data above (Figures 3.15 and 3.16) 
and previous report (Goldblatt et al., 2009a).  Although we extended our study as long 
as possible so that metastatic lesions would be able to grow larger, we actually had to 
discontinue our study one week earlier than the pilot study due to large tumor burden 
impairing the animals of the saline control group (Table 3.4).  H&E staining revealed the 
xenograft HCC1954 cells did not consistently metastasize in this study and only a few 
animals had any tumor cell infiltration into the lungs (Table 3.5).   
 
Imetelstat Treated Xenograft Cells Have Decreased CSC Features 
We next wanted to determine whether the decrease we observed in the CSC 
population in vitro could also be observed in vivo.  Imetelstat alone decreased the CSC 
population to levels similar as combination treatment (Figures 3.16‒18) and we have 
previously shown imetelstat decreases lung metastases; therefore, we chose to use a 
cell line model which reliably metastasizes to the lungs without primary tumor resection, 
TMD-231 breast cancer cells, since we were unable to consistently observe metastasis 
with the HER2+ HCC1954 xenograft cell line (Chen et al., 2013; Hochreiter et al., 2006).  
TMD-231 cells do not express HER2 amplification so trastuzumab is ineffective in these 
cells and was not studied. In accordance with our previous report, imetelstat significantly 
decreased tumor growth (Figure 3.30 A) and appeared to decrease lung metastases; 
although, lungs were too overtaken with tumor cells to quantitate the metastatic index  
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Table 3.5.  Xenograft HCC1954 Study Lung Metastases Observations. 
 
 
 
Animals were sacrificed after 10 weeks and lungs were resected, formalin fixed, paraffin 
embedded, and stained with H&E.  Lung tissue slides were analyzed by a pathologist 
and observations were recorded.   
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Figure 3.30.  Imetelstat Decreases TMD-231 Primary Tumor Growth and Lung 
Metastases.  A) Final tumor volume (length x width2/2) determined by caliper 
measurements of TMD-231 tumors in PBS (n=7) and imetelstat (n=7) treated NSG mice, 
Students t-test, *** p < 0.001 B) H&E staining of lungs resected 7 weeks post inoculation 
following PBS or imetelstat treatment.   
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(Figure 3.30 B).  The primary tumor tissue from this study was mechanically and 
enzymatically digested to generate a single cell suspension.  These primary xenograft 
tumor cells were then grown in monolayer culture or subjected to flow cytometry analysis 
of CSC marker expression.  The PBS treated xenograft cells had a more mesenchymal-
like phenotype characterized by the elongated morphology and reduced cell-cell contact, 
a phenotype typical of breast CSCs (Mani et al., 2008), whereas the imetelstat treated 
xenograft cells had more epithelial features, namely rounder morphology with more cell-
cell contact (Figure 3.31 A).  Furthermore, there was a trend of decreased CSC marker 
expression in imetelstat treated xenograft cells compared to vehicle control, but this 
decrease was not statistically significant due to higher variability in the PBS group with a 
near outlier and small sample size (Figure 3.31 B).  These data suggest imetelstat can 
target the CSC population in vivo.   
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Figure 3.31.  Imetelstat Decreases TMD-231 CSC Features.  A) Resected primary 
TMD-231 tumors digested and cultured as xenograft cells.  Imetelstat treated cells 
appear more epithelial while PBS treated cells have a predominately mesenchymal 
phenotype, 10X magnification, 60 µm scale bar.   B) Flow cytometry analysis of CSC 
marker expression of primary TMD-231 tumors from Figure 3.30.  Average is lineated, 
Students t-test, p = 0.12.    
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CHAPTER FOUR 
DISCUSSION 
 
In this thesis, we show HER2+ CSCs have active telomerase that can be 
inhibited by imetelstat treatment, leading to telomere shortening.  Imetelstat treatment 
alone, and in combination with trastuzumab, decreased the number of CSCs, as well as 
their functional ability, as shown by decreased mammosphere count and invasive 
potential.  Moreover, imetelstat was able to decrease the CSC population and 
mammosphere formation in a Triple Negative Breast Cancer cell line, TMD-231.  We 
report the first in vivo study of imetelstat and trastuzumab combination, in which the 
combination treatment had a slower tumor growth rate than either drug alone.  
Additionally, we found a trend toward lower CSC marker expression in imetelstat treated 
xenograft cells compared to PBS control, although this was not statistically significant 
due to small sample size and a near outlier in the PBS group.   
 Imetelstat has previously been shown to decrease the CSC population (Castelo-
Branco et al., 2011; Joseph et al., 2010; Marian et al., 2010a; Marian et al., 2010b).   
These studies mainly analyzed marker expression and spheroid formation following 
imetelstat treatment and did not investigate invasive and metastatic potential or 
combination with standard of care therapies.  This study is the first to propose the 
decreased metastases and invasion following imetelstat treatment are due to decreased 
CSCs.  Moreover, we are the first to investigate the effect of imetelstat and trastuzumab 
combination therapy on the CSC population. 
 Telomerase inhibition therapies have a long lag time from start of treatment to 
cell death or senescence due to their mechanism of action.  Cells must undergo a large 
number of cell divisions before telomeres become critically short and signal a DNA 
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damage response or growth arrest, suggesting telomerase inhibitors would be most 
effective when used in combination with standard therapies that have a rapid inhibitory 
effect on tumor cells.  Furthermore, telomerase inhibitors, like imetelstat, will be best 
tolerated when used in combination with agents that have different dose-limiting 
toxicities, such as targeted therapies like trastuzumab that have very few hematological 
side effects.  Indeed, the dose-limiting toxicities of imetelstat and trastuzumab 
combination therapy have been studied in a Phase I clinical trial in refractory HER2+ 
metastatic breast cancer patients (NCT01265927, www.clinicaltrials.gov).   
 Interestingly, we observed a decrease in the CSC population following imetelstat 
treatment both prior to telomere shortening and after telomere shortening, suggesting 
the effect of imetelstat on the CSC population occurs in telomere length dependent and 
independent mechanisms, as also reported by Brennan and colleagues when looking at 
short and long-term treatment with imetelstat on the multiple myeloma CSC fraction 
(Brennan et al., 2010).  In the study by Brennan, 72 hour treatment with imetelstat 
decreased mRNA expression of 5 genes important in CSC cell-fate decisions and self-
renewal, suggesting imetelstat can target the CSC population by impacting essential 
stem cell pathways during stem cell-fate decisions independent of telomere length.  
Additionally, long-term treatment with imetelstat inhibited clonogenic survival of multiple 
myeloma CSCs, suggesting imetelstat modulates CSC growth and self-renewal through 
decreasing telomere length (Brennan et al., 2010).  In our study, the CSC and non-CSC 
populations have similar telomerase activity and average telomere length, discounting 
the possibility that CSCs have shorter baseline telomeres and thus require less time to 
reach critically short lengths.  However, it is possible that CSCs have one or a few very 
short telomeres that are sufficient to signal telomere uncapping after short-term 
telomerase inhibition.  It is unlikely the decrease in the CSC population after just 12 days 
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of treatment is due to changes in telomere length, supporting the notion imetelstat can 
also work in telomere length independent mechanisms.   
 The noncanonical functions of telomerase have recently been investigated 
(reviewed in (Li and Tergaonkar, 2014)) and may elucidate how imetelstat impairs CSCs 
independent of telomere shortening.  Distinct from its activity at telomeres, telomerase 
can activate NF-κB mediated transcription and regulate NF-κB target gene expression 
by binding to the p65 subunit of NF-κB and being recruited to NF-κB promoters such as 
IL-6,TNF-α, and metalloproteinases (Ding et al., 2013; Ghosh et al., 2012).  Additionally, 
TERT serves as a transcriptional modulator of the Wnt/β-catenin signaling pathway by 
binding to the promoter of Wnt-dependent genes (Park et al., 2009).  Furthermore, 
TERT, BRG1, and GNL3L/NS form a complex necessary to maintain the function of 
CSCs (Okamoto et al., 2011).  Both NF-κB and Wnt are critical pathways in CSC 
maintenance.  NF-κB regulates CSC self-renewal both cell autonomously and non-
autonomously (Liu et al., 2010; Yamamoto et al., 2013).  Wnt/β-catenin regulates self-
renewal and proliferation of CSCs (Hallett et al., 2012; Liu et al., 2004).  It could be 
possible the decrease we see in CSCs following imetelstat treatment is related to the 
transcriptional activity of telomerase on NF-κB and/or Wnt signaling independent of 
imetelstat causing shortening of telomeres.  The inhibition of telomerase activity through 
imetelstat is more complex than simply shortening telomere length and warrants further 
investigation.    
Another potential telomere independent mechanism to explain the effect of 
imetelstat on CSCs could be due to reversal of the epithelial mesenchymal transition 
(EMT).  EMT activation is associated with maintenance of stem cell properties and 
acquisition of invasive and metastatic properties; EMT is able to generate CSCs (Gupta 
et al., 2009; Mani et al., 2008; Morel et al., 2008).  The hallmarks of EMT are loss of E-
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cadherin, which is associated with adherence junction disassembly, and expression of 
vimentin and fibronectin (Christiansen and Rajasekaran, 2006).  We did observe a 
change in cellular phenotype of imetelstat treated xenograft cells compared to PBS 
treated (Figure 3.31 A).  EMT is crucial for the initial steps of metastasis, including local 
invasion, intravasation, systemic transport, and extravasation; however, cells must then 
undergo a reversion of EMT termed MET to colonize a metastatic lesion (Tsai and Yang, 
2013).   Interestingly, a recent study investigated the off-target effects of imetelstat, 
including the cell rounding and loss of attachment frequently observed following 
imetelstat treatment.  This study found imetelstat disrupts the cytoskeleton through 
changes in actin, tubulin, and intermediate filament organization; furthermore, imetelstat 
decreases MMP2 expression and subsequently invasive ability of lung cancer cells 
(Mender et al., 2013).  Of note, this study also found imetelstat treatment resulted in a 
loss of E-cadherin, which could suggest cells have undergone EMT, but are unable to 
subsequently undergo MET and cannot adhere to colonize a metastatic lesion.   
While EMT has been closely associated with CSCs, other studies suggest cells 
that undergo EMT are not the cells responsible for metastases (Tsuji et al., 2008).  
Studies were carried out by Liu and collaborators to better understand the relationship 
between EMT, MET, and CSCs and furthermore distinguish between CD44+/CD24- 
CSCs and ALDH+ CSCs (Liu et al., 2014).  Gene expression analysis using microarrays 
was performed on isolated CD44+/CD24- or ALDH+ cell populations from primary breast 
cancer tissue.  The researchers found many genes displayed reciprocal expression 
patterns between CD44+/CD24- and ALDH+ cell populations; for example, mRNA 
transcripts elevated in CD44+/CD24- population were diminished in the ALDH+ cell 
population.  However, a set of transcripts expressed in CD44+/CD24- and ALDH+ cell 
populations overlapped with spheroid-forming cells, likely representing genes involved in 
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stem cell function.  These results suggest two stem cell compartments in human breast 
cancers are identified by CSC markers.  Moreover, CD44+/CD24- CSCs were 
significantly enriched in EMT- associated genes and ALDH+ CSCs were elevated in 
genes associated with the epithelial-like state (Liu et al., 2014).  Furthermore, purified 
CD44+/CD24- or ALDH+ cells were able to generate heterogeneous populations and 
recapitulate the CD44+/CD24- and ALDH+ proportions present in the original cell line in 
vitro, suggesting CSCs display plasticity and are able to reversibly transition between the 
mesenchymal-like CD44+/CD24- CSC state and the epithelial-like ALDH+ CSC state (Liu 
et al., 2014).   This switching between two distinct EMT and non-EMT CSC populations 
is supported by work in squamous cell carcinoma in which CSCs behaved likewise 
(Biddle et al., 2011).  Of note, it may be important to target both CSC populations as 
they can alternate between the two states (Liu et al., 2014).  Importantly, in this thesis, 
we show imetelstat alone and in combination with trastuzumab is able to decrease 
CD44+/CD24- and ALDH+ CSCs in a number of cell lines and most notably in the 
HCC1569 cell line, which displays both CSC populations. 
The ability of cells to undergo EMT and MET and thus cross back and forth 
between epithelial and mesenchymal states is known as epithelial mesenchymal 
plasticity (EMP) (Pinto et al., 2013).  Circulating tumor cells are thought to display EMP 
and share both epithelial and mesenchymal markers (Armstrong et al., 2011; Bednarz-
Knoll et al., 2012).  Furthermore, in a xenograft model using MDA-MB 468 cells, EMT is 
exhibited by cells at the tumor periphery while lymph node and lung metastases are 
mainly epithelial (Bonnomet et al., 2012).  Additionally, metastases from a xenograft 
MDA-MD-231 model exhibited epithelial marker expression, while these cells are highly 
mesenchymal in vitro (Chao et al., 2010).  Thus, the plasticity allowing cells to transition 
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between epithelial and mesenchymal-like states may play a critical role in metastasis 
formation (Liu et al., 2014). 
In summary, our results show imetelstat treatment of HER2+ breast cancer cells 
leads to telomerase inhibition and decreases the CSC population alone and in 
combination with trastuzumab.  Markedly, imetelstat and trastuzumab combination is 
able to decrease the percentage of CD44+/CD24- and ALDH+ CSCs in the same cell line, 
suggesting this combination would be effective in targeting CSCs because we are able 
to target both subsets and thus cells would not benefit from transitioning to the other 
CSC state, which could potentially occur if we were only able to target one CSC state.  
Imetelstat decreased the self-renewal potential as well as invasive potential of the CSC 
population alone and in combination with trastuzumab.  CSCs are thought to be 
responsible for recurrent and metastatic disease and our study suggests adding 
imetelstat to trastuzumab treatment may provide a more durable clinical response for 
HER2+ breast cancer patients.   
98 
 
CHAPTER FIVE 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The overall goal of this research project was to gain insight into the role of 
telomerase inhibition on the CSC population in breast cancer cells.  Additionally, we 
wanted to expand our studies on imetelstat and trastuzumab combination treatment in 
additional cell lines, as well as in vivo.  The work presented in this thesis demonstrates 
HER2+ CSCs have active telomerase that can be inhibited by imetelstat treatment, 
leading to telomere length shortening.  Additionally, we show imetelstat alone, and in 
combination with trastuzumab, can significantly decrease the CSC population and their 
self-renewal and invasive potentials.  Moreover, we observed a significant inhibition of 
tumor growth in combination treated mice compared to saline control treated mice, as 
well as the slowest tumor growth rate in combination treated mice.  Furthermore, cells 
from imetelstat treated xenograft tumors were morphologically different and exhibited a 
trend toward decreased CSC marker expression compared to cells from saline treated 
xenograft tumors. 
This study is novel in that assessment of imetelstat in combination with a 
standard of care therapy on the CSC population has not previously been reported.  One 
of the major concerns of telomerase inhibitors is the long lag period needed to shorten 
telomeres to critical levels before they undergo senescence or cell death.  To overcome 
this obstacle, telomerase inhibition is combined with agents that have a swift mechanism 
of action on cancer cells, notably paclitaxel and trastuzumab in breast cancer patients.  
Imetelstat has previously been shown to target the CSC population as a single agent, 
but the effects of imetelstat in combination with other agents was unknown (Castelo-
Branco et al., 2011; Joseph et al., 2010; Marian et al., 2010a; Marian et al., 2010b).  In 
this study, we show imetelstat and trastuzumab combination treatment can inhibit the 
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CSC population as effectively as imetelstat alone and potentially enhanced at some 
study points.  It would be interesting to determine the effects of imetelstat in combination 
with other therapeutic agents, such as paclitaxel and doxorubicin, on the CSC 
population.  Standard chemotherapeutic agents have been shown to increase the CSC 
population and it would be interesting to see if combination with imetelstat is able to 
overturn the increase in CSCs (Li et al., 2008). 
HER2 overexpression and/or amplification is a major driver of pathogenesis in 
breast cancer, and it is also becoming more apparent the importance of HER2 
overexpression in other cancer types as well.  Up to 30% of gastric cancers are HER2+, 
prompting the ToGA trial to determine the efficacy and safety of trastuzumab and 
subsequently FDA approval for the use of trastuzumab in advanced gastric cancers 
(Boku, 2014).  HER2 overexpression has also been observed in up to 50% of uterine 
serous carcinomas and up to 30% of endometrial cancers, leading to clinical trials to test 
trastuzumab efficacy and safety in these cancer types (Diaz-Montes et al., 2006; 
Morrison et al., 2006).  More recently, HER2 amplification was found in up to 20% of 
esophageal adenocarcinomas and the addition of trastuzumab to standard of care is 
being evaluated (Hu et al., 2011).  It would be interesting to examine the use of 
imetelstat and trastuzumab combination therapy in these HER2+ cancer subtypes and 
determine if imetelstat can augment the effects of trastuzumab similar to what we have 
demonstrated in breast cancer.  Additionally, it may prove beneficial to examine the 
effect of trastuzumab and imetelstat combination treatment on the CSC populations of 
these cancer subtypes as well. 
Telomerase plays a critical role in normal stem cell self-renewal and 
differentiation (Choi et al., 2008).  It has been reported that alterations in CSC number 
correlates with changes in expression of stem cell related genes, suggesting 
differentiation of CSCs when they are targeted (Brennan et al., 2010; Korkaya et al., 
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2008).  As we have shown a decrease in CSCs after imetelstat and combination 
treatment with trastuzumab in this study, it is important to determine what results from 
this decrease.  To determine if our treatments are inducing differentiation of CSCs, we 
would perform real-time PCR to measure mRNA expression of stem cell related genes, 
for example, OCT3/4, SOX2, NANOG, BMI1, JAG1, and GLI1.  Alternatively, the 
decrease in CSCs could be due to induction of cell death.  To determine if our 
treatments are inducing apoptosis of CSCs, we would measure Annexin V and 
propidium iodine staining by flow cytometry and perform western blotting to determine 
caspase cleavage. 
In this study, we also show imetelstat alone and in combination with trastuzumab 
decreases invasive potential of HCC1569 cells.  While the invasive potential for 
HCC1569 cells is much lower than other breast cancer cell lines, such as MDA-MD-231, 
we extended the length of the experiment and were able to see some cells had invaded 
through the basement membrane invasion assay (Neve et al., 2006).  To further explore 
the effects of imetelstat and combination with trastuzumab on invasive and metastatic 
potential, it would be useful to measure changes in invasion and metastasis associated 
proteins.  We would use real-time PCR to analyze mRNA expression of matrix 
metalloproteinases (MMP2, MMP3, and MMP9) used to break down extracellular matrix 
and the metastasis associated proteins (MTA1, MTA2, and MTA3).   
This study is the first to report a significant inhibition of tumor formation in a 
xenograft animal model using imetelstat and trastuzumab combination treatment.  We 
were unable to distinguish tumor volume differences between trastuzumab treated mice 
and combination treated mice due to cessation of the study because of tumor burden in 
the saline treated animals.  To determine whether combination treatment can inhibit 
tumor formation better than trastuzumab alone, it would be important to perform modified 
survival studies in vivo, where animals are sacrificed once tumors reach a set volume, 
101 
 
as has previously been used to study other agents in combination with trastuzumab 
(Garrett et al., 2013).  Additionally, use of a less immunocompromised mouse strain, 
such as athymic nude mice which still have Natural Killer (NK) cells, would provide a 
better model of primary tumor growth response to trastuzumab and combination 
treatment, as antibody-dependent cell cytotoxicity mediated through NK cells is thought 
to be a main mechanism of trastuzumab action (Bianchini and Gianni, 2014).  
While we show decreased lung metastases using the TNBC cell line TMD-231 
following imetelstat treatment, we were unable to consistently form metastatic lesions 
using the HER2+ breast cancer cell line HCC1954 and therefore could not study the 
effect of imetelstat and trastuzumab combination on metastasis formation.  Developing a 
representative metastatic model has proven difficult in HER2+ breast cancers, although a 
few have been described.  Infection of a metastatic cell line, such as TMD-231, with a 
lentivirus containing HER2, would generate a HER2+ metastatic model, but could lack 
the relevant pathology of this subtype due to exogenous overexpression of HER2.  Yu 
and colleagues were able to generate lung metastases and liver metastases (80% and 
60% incidence rates, respectively) after tertiary serial passage in vivo of the HER2+ 
breast cancer cell line SKBR3 (Yu et al., 2007).  Additionally, Nanni and collaborators 
developed a model of multiorgan metastases of HER2+ human breast cancer cells using 
highly immunodeficient Rag2−/−;Il2rg−/− (also called Rag2−/−;gamma−/−) mice and 
orthotopic implantation of 107 MDA-MD 453 or BT474 with metastatic incidences of 
100% and 67%, respectively (Nanni et al., 2012).  It would be beneficial to determine the 
effect of trastuzumab and imetelstat combination on metastatic potential and one of the 
above models could help us do so. 
As discussed in Chapter Four, telomerase can activate NF-κB mediated 
transcription and regulate NF-κB target gene expression, as well as serve as a 
transcriptional modulator of the Wnt/β-catenin signaling pathway (Ding et al., 2013; 
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Ghosh et al., 2012; Park et al., 2009).  As NF-κB and Wnt signaling pathways are 
essential in CSC maintenance, it is possible inhibition of telomerase by imetelstat 
impacts regulation of these signaling pathways and may explain the decrease in CSCs 
after imetelstat treatment.  It is worthwhile to investigate whether binding of TERT to the 
NF-κB p65 subunit is altered after imetelstat treatment.  Additionally, investigating gene 
expression of NF-κB dependent genes before and after imetelstat treatment would be of 
interest as telomerase regulates expression of these genes, many of which are 
important in cancer progression.  Moreover, TERT activates the Wnt pathway by acting 
as a cofactor in a β-catenin transcriptional complex, although recent work suggests this 
may be cell type and experimental system dependent (Listerman et al., 2014).  
Nonetheless, in a study of esophageal cancer, telomerase variants found in patient 
samples decreased telomere length, depleted β-catenin, down regulated canonical Wnt 
signaling, and significantly decreased tumorigenicity of esophageal cancer cells (Zhang 
et al., 2014).  It would be interesting to investigate Wnt pathway activation after 
imetelstat treatment. 
As telomerase plays an important role in normal stem cell function, another 
serious concern of telomerase inhibition used as an anti-cancer therapeutic is the effect 
on normal stem cells.  The most common toxicities of patients receiving imetelstat are 
neutropenia, thrombocytopenia, and lymphopenia and in the only clinical trial data 
published, 2 of 6 patients had dose-limiting myelosuppression (Thompson et al., 2013).  
As Hematopoietic Stem Cells (HSCs) are one of the most rapidly dividing cells in the 
body, it is not surprising patients develop low blood cell counts after receiving 
telomerase inhibitors.  Indeed, telomerase deficient murine HSCs can be serially 
transplanted less than half as many rounds as wild-type HSCs and have approximately a 
2-fold increase in rate of telomere shortening, suggesting telomerase maintains 
replicative capacity of HSCs by countering telomere shortening that occurs with every 
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cell division (Allsopp et al., 2003).  It would be interesting to investigate the 
consequences of telomerase inhibition therapy on HSCs and hematopoietic progenitor 
cells.  HSCs are defined as CD34+, CD59-, Thy1/CD90+, CD38-, C-kit/CD117+, lin-.  Flow 
cytometry could be used to measure the percentage of HSCs after imetelstat treatment.  
Notably, bone marrow aspirates were collected from patients enrolled in the Phase I 
study of imetelstat and trastuzumab combination in refractory HER2+ metastatic breast 
cancer and could be used for these studies.  Studying the effect of telomerase inhibition 
on the normal HSC compartment would provide insight into the toxicities observed in 
patients receiving imetelstat. 
In conclusion, we report here imetelstat treatment decreases the CSC population 
alone and in combination with trastuzumab.  Strikingly, imetelstat and trastuzumab 
combination is able to decrease the percentage of CD44+/CD24- (mesenchymal-like 
CSCs) and ALDH+ (epithelial-like CSCs) populations in the HCC1569 cell line, 
suggesting this combination would be highly effective in targeting CSCs.  Both epithelial-
like CSCs and mesenchymal-like CSCs are decreased; thus, cells would have no 
advantage or escape route by transitioning to the other CSC state, which could 
potentially occur if we were only able to target one CSC state.  Imetelstat decreased the 
self-renewal potential as well as invasive potential of HCC1569 cells alone and in 
combination with trastuzumab.  CSCs are thought to be responsible for recurrent and 
metastatic disease, which leads to most cancer deaths.  Our study suggests adding 
imetelstat to trastuzumab treatment may provide a more durable clinical response in 
HER2+ breast cancer patients.   
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